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Foxp3+ regulatory T cells (Treg cells) are essential for establishing and maintaining self-
tolerance, and also inhibit immune responses to innocuous environmental antigens. Imbal-
ances and dysfunction in Treg cells lead to a variety of immune-mediated diseases, as
deficits in Treg cell function contribute to the development autoimmune disease and
pathological tissue damage, whereas overabundance of Treg cells can promote chronic
infection and tumorigenesis. Recent studies have highlighted the fact thatTreg cells them-
selves are a diverse collection of phenotypically and functionally specialized populations,
with distinct developmental origins, antigen-specificities, tissue-tropisms, and homeostatic
requirements. The signals directing the differentiation of these populations, their specifici-
ties and the mechanisms by which they combine to promote organ-specific and systemic
tolerance, and how they embody the emerging property of regulatory memory are the
focus of this review.
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INTRODUCTION
It has become increasingly accepted that most individuals have
self-reactive lymphocytes circulating throughout their periph-
eral tissues. In the wrong context, these cells may be capable
of mediating pathogenic autoimmune responses. By contrast, in
healthy individuals, these cells are counterbalanced by regulatory
cells, which act to stably suppress the pathogenic potential of
self-reactive cells. Regulatory T (Treg) cells, a subset of CD4+
T cells defined by their expression of the transcription factor
Foxp3, constitute a major immune-regulatory cell population in
the body. The majority of Treg cells arise during T cell develop-
ment in the thymus, where moderate- to high-avidity recognition
of self-antigen leads to the development of Foxp3+ thymic Treg
(tTreg). The second pathway of Treg generation is in the periph-
ery, where mature, naïve CD4+ T cells develop into peripheral Treg
(pTreg) cells upon antigen encounter under certain conditions (1).
The choice between tolerance (i.e., control of inflammation) and
autoimmunity is determined to a significant extent, by the relative
generation and maintenance of pathologic effector T cells (Teff)
and protective Treg cells specific for self-antigens. An imbalance in
this number or activity of Treg cells is thought to underlie many
inflammatory and autoimmune disorders. When Treg cells are
absent or rendered non-functional, both mice and human beings
develop fulminant and life-threatening autoimmunity (2). Addi-
tionally, genome-wide association studies have identified several
genes involved in the development, maintenance, or function of
Treg cells that are linked to autoimmune disease susceptibility (3).
In addition to preventing autoimmunity and maintaining immune
homeostasis, Treg cells are required to minimize tissue damage in
inflammatory settings such as viral infection (4) or mediate toler-
ance to allografts (5). However, Treg cell-mediated suppression can
also have undesirable effects such as the development of chronic
infection or suppression of anti-tumor responses. Indeed, Treg
cells are now considered a promising target in cancer therapy (6).
In order to therapeutically manipulate Treg cell numbers or
function, a multitude of studies have defined the factors required
to generate and maintain these cells, and characterized the mech-
anisms of how they mediate their regulatory functions in various
settings. An emerging concept is that Treg cells are a phenotyp-
ically and functionally heterogeneous population, with specific
subsets requiring different factors for their differentiation, mainte-
nance, and function in different inflammatory contexts or tissues.
In this review, we discuss the diversity of Treg cells in periph-
eral tissues and identify some of the key open questions in Treg
biology that present potential opportunities and roadblocks for
the therapeutic manipulation of Treg cells. These include the
development, specificity, and maintenance of specialized Treg cell
populations, a better understanding of the effector mechanisms
Treg cells employ, and how they manage to discriminate between
potentially harmful and beneficial responses. We also discuss the
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emerging concept of regulatory memory, and how Treg cells may
also fulfill non-immune tissue-support functions.
PHENOTYPIC DIVERSITY OF Treg CELLS
When initially described in the mid-1990s, Treg cells were identi-
fied based on their constitutive expression of the CD25 component
of the high-affinity IL-2 receptor complex (7). However, the iden-
tification of Foxp3 as the specific transcription factor that drives
Treg cell development and function (8, 9), and the generation
of experimental tools for analysis of Foxp3 expression allowed
for more thorough examination of the phenotypic diversity of
Treg cells (10). It quickly became apparent that like conventional
CD4+ effector cells that can be divided into functionally distinct
effector populations based on differential expression of adhesion
and chemoattractant receptors, Treg cells could also be extensively
sub-divided based on expression of homing receptors expected
to target them to both lymphoid and non-lymphoid tissues (11).
Indeed, Treg cells can be found in many tissues even in the absence
of any strong ongoing immune responses. Moreover, many stud-
ies over the last decade have demonstrated that Treg cells function
in both lymphoid and non-lymphoid tissues in order to prevent
inflammatory disease and maintain normal immune homeostasis
(12–18). Additionally, Treg cells are rapidly recruited to inflamed
tissues, where they dampen autoimmunity and prevent collateral
tissue damage during ongoing inflammation, but may also pro-
mote pathogen persistence and tumor development/growth. In
this section, we will briefly summarize the current understanding
of tissue- and inflammation-specific Treg cells.
ORGAN-SPECIFIC Treg CELLS ASSOCIATED WITH THE INTESTINES AND
SKIN
Because of their important barrier function, exposure to benign
commensal micro-organisms and food-derived antigens, and fre-
quent pathogen encounter, the intestines are immunologically
active organs that need to maintain a fine balance between pro- and
anti-inflammatory responses. Although this balance is the result
of a coordinated effort between many cell types, including intesti-
nal epithelial cells, dendritic cells (DCs), innate lymphoid cells and
conventional T cells, it is clear that Foxp3+ Treg cells have a central
role in maintaining normal intestinal immune homeostasis. This
is best exemplified by the fact that defects in Treg cell differentia-
tion or function result in development of intestinal inflammation
in both humans and mice (2, 19, 20). Additionally, one of the most
commonly used in vivo mouse models of Treg cell function mea-
sures their ability to block T cell-mediated inflammatory colitis
following adoptive transfer into lymphopenic mice (21). Consis-
tent with this, the intestines harbor a large population of Foxp3+
Treg cells. Migration of T cells to the intestine requires expres-
sion of high levels of the intestinal homing integrin α4β7. Given
the importance of Treg cells in maintaining intestinal immune
homeostasis, it may seem somewhat surprising that very few Treg
cells in adult peripheral blood are α4β7+ (22, 23). However, stud-
ies with parabiotic mice have demonstrated that in adults, most
intestinal T cells, including Treg cells, are tissue-resident and do
not actively recirculate (24, 25). Moreover, α4β7-expressing Treg
cells are abundant in umbilical cord blood (26), and together this
suggests that after initial development and seeding early in life,
intestinal Treg cells maintain themselves as a stable, self-renewing
population with little input from the periphery.
Because of the unique immunological challenges posed by
the intestine, intestinal Treg cells display several phenotypic and
functional properties distinct from other Treg cell populations.
First, given the large burden of benign, non-self-antigens that the
intestines are exposed to through the commensal microflora and
ingestion of food-derived antigens, it is not surprising that a large
fraction of the Treg cell population in the intestines, and espe-
cially in the colon, display phenotypic features consistent with a
peripheral origin (27–29). Indeed, feeding model antigens such
as ovalbumin to mice in their drinking water leads to efficient
generation of antigen-specific pTreg cells in the gut-associated
lymphoid tissues (30, 31). This is due to the presence of a spe-
cialized population of CD103+ DCs in the intestines and their
associated lymphoid tissues that can produce active TGF-β and
retinoic acid (RA), which together promote pTreg cell develop-
ment (30, 32). pTreg cell differentiation was also observed in cells
expressing cloned T cell receptors (TCRs) derived from intestinal
Treg cells,which had been generated in response to specific compo-
nents of the intestinal microflora (33). Interestingly, effector T cells
expressing these TCRs induced colitis in immunodeficient mice,
indicating that pTreg induction is an important mechanism by
which T cells specific for commensal antigens are tolerized in vivo.
However, it is important to note that not all commensal-specific T
cells undergo pTreg cell conversion, as T cells specific for flagellin
expressed by Clostridium bacterial species are potently activated
and undergo effector differentiation in mice when the epithelial
barrier is compromised during infection with the inflammatory
parasite Toxoplasma gondii (34). However, consistent with the
unique array of antigens they are exposed to, the TCR repertoire
of colonic Treg cells is distinct from that of colonic effector T cells,
and from Treg cells in other tissue sites (33).
In addition to their unique specificity, intestinal Treg cells are
also exposed to an environment rich in commensal and host
metabolites that can influence their development and function.
For instance, as mentioned above, RA (derived primarily from
dietary vitamin A) augments pTreg cell development in the intes-
tine, and also drives T cell expression of intestinal homing recep-
tors such as α4β7 integrin and the chemokine receptor, CCR9
(35). Additionally, the intestine contains a high concentration
of commensal-derived toll-like receptor (TLR) ligands that may
directly influence the abundance and function of Treg cells. For
instance, stimulation of Treg cells with TLR2 ligands can aug-
ment Treg cell proliferation but inhibit their suppressive activity
(36). Additionally, TLR ligands can impact Treg cell generation
and abundance in the intestine indirectly by altering cytokine
production and activation of other cell types. In this context, acti-
vation of TLR9 by DNA from commensal organisms enhances
inflammatory cytokine production that limits TGF-β-driven Treg
cell differentiation in vitro, and accordingly TLR9-deficient mice
have increased Treg cell abundance in intestinal tissues (37). Sim-
ilarly, IL-6 produced upon TLR ligation can both block pTreg cell
development (promoting Th17 cell differentiation instead) (38),
and inhibit the suppressive function of existing Treg cells (39).
Finally, a series of recent papers have demonstrated that certain
metabolites of the commensal flora can dramatically influence the
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development and maintenance of intestinal Treg cells. Specifically,
short-chain fatty acids (SCFA), such as butyrate, that are produced
by intestinal bacteria during the breakdown of dietary fiber pro-
mote pTreg cell differentiation in the intestine, and augment the
proliferation of existing intestinal Treg cells (40–42). The effects
of SCFA of intestinal Treg cells were dependent on the expression
of the free fatty acid receptor, GPR43, and are at least partially
due to the ability of SCFA to directly promote Foxp3 expression.
Accordingly, GPR43-deficient mice were highly sensitive to disease
development and showed impaired recovery in a model of chronic
inflammatory colitis (43). Interestingly, the effects of SCFA range
beyond the intestine, as GPR43-deficient animals were also more
sensitive to development of inflammatory arthritis and asthma.
However, GPR43 is also expressed by a range of myeloid cells, and
the specific contribution of impaired Treg cell function to these
inflammatory phenotypes has not been precisely delineated.
Like the intestine, the skin is a barrier tissue with a large com-
mensal microbial community that is frequently a site of pathogen
encounter/entry. Additionally, the skin is exposed to environ-
mental irritants and damage from ultraviolet light exposure, and
undergoes frequent traumatic injury and wound repair. Dys-
regulated immune responses in the skin result in a number of
inflammatory disorders, including contact hypersensitivity, atopic
dermatitis, psoriasis, and Pemphigus vulgaris, and it is therefore
not surprising that as in the intestines, there is a large population
of Treg cells in both mouse and human skin even in the absence of
overt inflammation (12, 22, 44). In human peripheral blood, most
Treg cells express functional skin-homing receptors such as the
functional E-selectin ligand cutaneous lymphocyte antigen (CLA)
and CCR4 (22, 23), and skin-tropic Treg cells in mouse have been
defined based on their expression of P- and E-selectin ligands,
CCR4 and CD103 (12, 13, 17). Additionally, multiple studies have
demonstrated that Treg cell migration to the skin is essential for
their ability to prevent inflammatory disease in the skin (12, 17),
and to regulate cutaneous immunity in the contexts of delayed-
type hypersensitivity responses and viral or parasitic infection (13,
45, 46). Furthermore, both mice and humans with impaired Treg
cell activity display severe skin inflammation (47, 48).
The size of the Treg pool in the skin may be controlled by
keratinocyte-derived IL-7, an essential factor for their mainte-
nance in murine skin (49). In addition to the production of
IL-7 (50), keratinocytes may indirectly regulate inflammation via
expression of the TNF-family molecule, RANKL. Skin inflamma-
tion (triggered by UV-light and prostanoids) increases RANKL
production by keratinocytes. RANK/RANKL interactions lead to
activation of skin-resident DCs and preferential expansion of Treg
cells in skin-draining lymph nodes (51). Moreover, similar to the
gut, RA-producing skin-derived DCs are capable of triggering the
generation of Treg cells. However, in the skin, RA production is
restricted to CD103−DCs (52). Interestingly,TLR triggering or the
presence of a commensal microflora was not essential to induce
RA production.
Despite their clear importance in regulating immune responses
in the skin, far less is known regarding the developmental origin,
specificity, and function of cutaneous Treg cells as compared with
Treg cells in the intestines. The notion that Treg cells in the skin
have a unique specificity profile is supported by data indicating
that the TCR repertoire of Treg cells in the skin-draining inguinal
and axillary lymph nodes of mice differs substantially from that of
Treg cells found in the spleen or mesenteric lymph nodes (53).
However, the fine specificity of cutaneous Treg cells is almost
entirely uncharacterized. Given the complex microbial communi-
ties resident on the skin, one would expect that as in the intestine
many cutaneous Treg cells would recognize these foreign anti-
gens. However, to date the limited data available regarding Treg
cell specificity in the skin suggest that cutaneous Treg cells are
largely specific for self-antigens. For instance, Treg cells with a skin-
tropic phenotype were found in transgenic mice expressing a TCR
cloned from skin-reactive CD4+ T cells found in Foxp3-deficient
mice (54). Although the precise antigen recognized by these cells
was not defined, they reacted equally well to DCs from the skin-
draining lymph nodes of specific-pathogen free and germ-free
mice, indicating that they are not specific for cutaneous com-
mensals. Additionally, Treg cells specific for an inducible, trans-
genic self-antigen rapidly accumulated in the skin when antigen
expression was activated (55).
Interestingly, Treg cells appear to occupy a specialized anatomic
niche in the skin, accumulating in and around the epithelial invagi-
nations associated with hair follicles (44, 49). Recent data have
indicated that hair follicles can act as specialized immune struc-
tures that coordinate immune cell migration and function in the
skin. This may relate to the fact that skin appendages such as
hair follicles, sweat glands, and sebaceous glands house diverse
and unique microbial communities that interact with and shape
the cutaneous immune system (56). Indeed, there was a pro-
nounced increase in the frequency and number of Treg cells in
the skin of germ-free mice, indicating that interactions with cuta-
neous commensal flora help regulate Treg cell abundance in the
skin (57). Moreover, this study demonstrated that commensal-
dependent production of IL-1 in the skin is essential for inflam-
matory immune responses to the parasite Leishmania major, and
this may in part be due to the ability of IL-1 to suppress Treg cell
function (58).
Aside from the skin and intestine, other non-lymphoid tissues
with large numbers of Treg cells in the steady-state include the
lungs, liver, adipose tissue, and skeletal muscle. Like the skin,
the lungs and the liver are major targets of the organ-specific
inflammatory disease that develops in Foxp3-deficient mice (48),
suggesting that Treg cells in these organs have an important func-
tion in maintaining hepatic and pulmonary immune homeostasis.
The function of Treg cells in other tissues, including potential
“tissue-support” functions in the adipose tissue and muscle will be
addressed later in this review.
INFLAMMATION-SPECIFIC Treg CELLS
In addition to Treg cells that constitutively reside in tissues such
as the skin and intestine, Treg cells are rapidly recruited to sites of
inflammation. In many sites, Treg cells recruited during inflam-
mation accumulate over time and persist even after inflammation
has resolved. For instance, skin inflammation in an autoimmune
setting results in the generation and recruitment of Treg cells to
the skin where they steadily increase in abundance to make up
60–80% of the skin-resident CD4+ T cell population, and help
resolve the inflammatory response (55, 59). T cell recruitment
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to inflamed tissues is the result of dramatic changes in expres-
sion of chemokines, adhesion molecules, and extracellular matrix
components that occur during tissue inflammatory responses.
Importantly, these changes often act to amplify the inflammatory
response in feed-forward loops. For instance, during inflamma-
tory responses dominated by IFN-γ-producing Th1 cells, IFN-γ
induces the expression of the chemokines CXCL9 and CXCL10
by tissue-resident cells, which act to further the recruitment of
CXCR3+ Th1 cells (60). Similarly, IL-17A and IL-17F produced
by Th17 cells can amplify the recruitment of CCR6+ Th17 cells
by inducing expression of the chemokine, CCL20 (61). Moreover,
expression of CXCR3 and CCR6 is controlled by the Th1 and
Th17 lineage-specifying transcription factors, T-bet and RORγt,
respectively, and this links the functionality of these cells to their
ability to access different inflammatory sites (61, 62). The realiza-
tion that distinct populations of both human and mouse Treg cells
express these and other inflammatory homing receptors raised the
possibility that specialized populations of Treg cells are recruited
to different types of inflammatory responses, and that these may
share molecular characteristics with pro-inflammatory helper T
cell populations. In fact, several recent studies have demonstrated
that regulation of Th1, Th2, and Th17 responses by Treg cells has
distinct molecular requirements (63–65). Moreover, populations
of Treg cells that phenotypically mirror effector T cell subsets and
share expression of key transcription factors such as T-bet and
RORγt have been identified in both mouse and human (63, 66–
69). In addition to these “lineage-specific” transcription factors,
in mice the function of these effector Treg cell populations was
dependent on upregulation of the transcription factor Blimp-1
following Treg cell activation (70).
The ability of Treg cells to be rapidly mobilized to inflamed tis-
sues has led to the somewhat paradoxical observation that the
number of Treg cells is often elevated in target tissues during
autoimmune and inflammatory diseases, including inflammatory
bowel disease, multiple sclerosis and rheumatoid arthritis (71–73).
Similar studies have also observed Treg cell accumulation in multi-
ple mouse models of autoimmune disease (74, 75). Although this
likely represents an effort by the immune system to re-establish
proper control of the autoimmune response, the inability of these
tissue-infiltrating Treg cells to effectively modulate disease suggests
that they are somehow functionally compromised in vivo. This can
occur as the result of inflammatory cytokines that either directly
inhibit Treg cells or render effector T cells and other immune cells
resistant to Treg cell-mediated suppression (76).
The formation of stable Treg cells requires two independent
processes: the expression of Foxp3 and the establishment of a
Treg cell-specific CpG hypomethylation pattern, both of which
require TCR stimulation (77). This hypomethylation is the basis
for Treg-specific gene expression, lineage stability, and full sup-
pressive activity. A recent study has found that the main function
of Foxp3 is to act as a transcriptional repressor. Importantly, Foxp3
binding alone was not sufficient to establish suppression in rest-
ing Treg where Foxp3-bound regulatory elements are only poised
for repression. An inflammatory stimulus was then required to
incorporate the polycomb-group histone methyltransferase Ezh2
into the complex and deposit repressive chromatin modifica-
tions at Foxp3-bound loci (78). This approach used systemic
inflammation caused by Treg cell depletion as inflammatory stim-
ulus and more research is required to identify the exact inflam-
matory signals that were sensed and led to chromatin remodeling.
However, this cross-talk between tissue inflammation and Treg
cell stability and function may serve to ensure that Treg cells that
have undergone an inflammatory response that they successfully
resolved are stable and more suppressive than resting Treg cells.
CRITICAL ISSUES IN Treg CELL BIOLOGY
Overall, the phenotypic diversity of Treg cells allows them to access
multiple tissue sites, where they maintain immune homeostasis by
both preventing initiation of immune responses in secondary lym-
phoid tissues and dampening ongoing inflammatory responses in
non-lymphoid organs. Their potent anti-inflammatory function
has led to efforts to boost Treg cell activity for treating autoim-
munity and chronic inflammation and preventing graft rejection
(79, 80). Conversely, transient inhibition of Treg cell function may
allow for more effective immune responses in the contexts of vac-
cination, persistent infection, and cancer. However, several key
questions regarding the development, specificity, function, and
maintenance of different Treg cell populations remain as key bar-
riers to clinical success. In this section, we will discuss some of
these issues, and how their resolution may contribute to successful
implementation of Treg cell-based immunotherapies.
Treg CELL SPECIFICITY
Like other CD4+ T cells, it is clear that Treg cell development
depends on expression of MHC class II molecules in the thy-
mus, against which they are positively and negatively selected (81).
Additionally, abundant evidence indicates that at least a large frac-
tion of Treg cells are self-antigen-specific. However, current knowl-
edge of the precise antigen-specificities of Treg cells is extremely
limited. As a result, some of the biggest unanswered questions
regarding Treg cells relate to their antigen specificity, and under-
standing how this influences their differentiation and homeostasis,
as well as their migratory and functional characteristics.
That Treg cells are largely autoreactive was initially inferred
based on the fact that they shared phenotypic features of acti-
vated T cells. For instance, in mice, most Treg cells display a
CD44hiCD45RBloCD25+ phenotype resembling activated con-
ventional T cells. Additionally, large (and somewhat overlapping)
subsets of Treg cells express other activation markers such as CD69,
ICOS, and CD38, and consistent with chronic antigen stimulation
Treg cells undergo a rapid rate of steady-state proliferation in vivo
(82). Analysis of the TCR repertoire of Treg cells demonstrated that
there is little overlap between the TCRs expressed by Treg cells and
conventional Foxp3− T cells, indicating that antigen specificity is a
key determinant in Treg cell differentiation (83). Additionally, this
study showed that when expressed in effector T cells, TCRs from
Treg cells can induce a wasting/autoimmune disease upon transfer
into lymphopenic recipients, further supporting the notion that
many Treg cells are indeed autoreactive. A key advance in under-
standing the self-reactivity of Treg cells came from analyses of TCR
transgenic mice. Although most TCR transgenic mice expressing
MHC class II restricted TCRs do develop a population of Treg cells,
this is usually dependent on rearrangement of endogenous TCR
genes and is therefore abrogated in RAG-deficient mice. However,

























































Gratz and Campbell Organ-specific Treg cells
in several cases providing their cognate antigen as either a tissue-
restricted or systemic transgene drives efficient Treg cell devel-
opment even in RAG-deficient TCR transgenic mice, definitively
demonstrating that recognition of self-antigens promotes Treg cell
differentiation (84–86). Accordingly, it has been postulated that
expression of AIRE, a transcription factor that promotes expres-
sion of tissue-restricted antigens in thymic medullary epithelial
cells, can influence Treg cell development (87, 88). However, the
extent to which AIRE influences the Treg cell repertoire remains
somewhat controversial (89). Nonetheless, the preponderance of
evidence clearly indicates that the vast majority of tTreg cells are
selected on the basis of self-antigen recognition in thymus,and that
this autoreactivity has dramatic consequences on their phenotype
and behavior in the periphery.
Although the self-reactivity of tTreg is well-accepted, the pre-
cise autoantigens recognized by Treg cells are almost completely
unknown. Classically, presentation of antigens by MHC class II
molecules was thought to be restricted to exogenous antigens taken
up into cells via the endocytic or phagocytic pathways. However, it
has become clear that the MHC class II antigen-processing path-
way can access almost any cellular protein either through uptake of
apoptotic cells or through autophagy of cellular contents. Indeed,
many self-peptides eluted from MHC class II molecules expressed
by activated B cells and macrophages were actually derived from
cytosolic proteins (90). Thus, the number of potential peptide–
MHC complexes that could drive Treg cell differentiation in the
thymus is likely very large. However, the fraction of these anti-
gens actually recognized by thymic and peripheral Treg cells is
unknown. The diverse TCR repertoire of Treg cells suggests that
they have broad reactivity (83). Interestingly, this may be enforced
during thymic development of Treg cells, as the efficiency of Treg
cell development for thymocytes of any given TCR is governed
by readily saturable “niches” that likely relate to antigen availabil-
ity (91), and this may help ensure that Treg cells specific for a
wide range of self-antigens are generated in the thymus. Similarly,
in the periphery competition for limited peptide–MHC niches
could help ensure that the Treg cell repertoire remains sufficiently
broad to maintain self-tolerance to the vast array of potential
tissue-specific and systemic autoantigens (92).
Further adding to the confusion regarding the differentiation
and specificity of Treg cells are the recent findings that Treg
cells specific for some pathogens expand during infection, and
can contribute to immune dysregulation and impaired pathogen
clearance (93). Surprisingly, unlike pTreg cells specific for com-
mensal microbes and other environmental antigens, in many cases
the pathogen-specific Treg cells were actually present in the pre-
infection Treg cell repertoire. For instance, in murine infection
with Mycobacterium tuberculosis, Treg cells specific for the immun-
odominant epitope ESAT64–17 were identified in the lung-draining
lymph nodes using peptide:MHC class II tetramers (94). Interest-
ingly, TCR Vβ utilization was distinct in the Foxp3+ vs. Foxp3−
ESAT6-specific cells, which suggested that they have different
developmental origins. Indeed, adoptive transfer studies defini-
tively established that ESAT6-specific Treg cells were derived from
pre-existing tTreg cells, and were not the product of pTreg cell
differentiation from naïve precursors. Similarly, Treg cells spe-
cific for epitopes of mouse hepatitis virus were found in the
pre-infection Treg cell pool (95), as were Treg cells reactive to
Leishmania major (although the precise epitopes in this case have
not been identified) (96). These studies raise several interesting
questions regarding Treg cell development, specificity, and func-
tion. Because Treg cell differentiation in the thymus depends on
high-affinity TCR triggering, what are the nature of the antigens
that drive the differentiation and maintenance of these pathogen-
specific Treg cells? How does expansion of pathogen-specific Treg
cells impact the outcome of subsequent pathogen encounters? Is
Treg cell specificity a virulence factor of pathogens that were evo-
lutionary selected to be recognized by Treg (i.e., are pathogens
that express peptides capable of triggering Treg cells more suc-
cessful)? Additionally, are TCRs expressed by Treg cells likely to
recognize multiple ligands due to the fact that their selection in
the thymus requires high-affinity interactions with self-MHC? In
this regard, despite the fact that most Treg cells are thought to
develop in response to recognition of self-antigen in the thymus,
broad reactivity to foreign antigens in Treg cells has also been
observed (97).
The relationship between TCR specificity and development of
the phenotypically and functionally specialized Treg cell popu-
lations discussed previously is also poorly understood. The fact
that Treg cells in different tissue sites have distinct TCR reper-
toires is strong evidence that Treg cell specificity impacts their
phenotype, homing receptor expression and tissue distribution
(53). Indeed, Treg cells in mice expressing a TCR specific for
a skin-expressed self-antigen acquire a skin-tropic P-/E-selectin
ligand+CCR4+ phenotype (54), likely through interaction with
skin-derived DCs in peripheral lymph nodes (98). Thus, efficient
Treg cell migration to the skin only happens when the antigen
is expressed at that site (55). In addition to indirectly control-
ling Treg localization by influencing homing receptor expression,
TCR triggering also induces potent “stop” signals that act to retain
antigen-specific T cells in tissues (99). The TCR may also control
Treg cell localization by directly mediating interactions between
Treg cells and vascular endothelial cells that promote cellular exit
from the blood into antigen-bearing tissues (100).
DEVELOPMENT OF SPECIALIZED Treg CELL SUBSETS
The existence of tissue- and inflammation type-specific Treg
cell subsets with specialized functions implies that Treg cell-
based immunotherapies must target correct Treg cell populations
in order to successfully modulate different types of immune
responses in distinct tissue sites. Additionally, the diversity of tis-
sue Treg cells suggests that they alter their migratory, functional,
and homeostatic properties in response to contextual cues from
the immune environment (101). However, the mechanisms guid-
ing the development of specialized Treg cell subsets, and the ways
in which they mirror and diverge from the comparatively well-
characterized pathways of effector T cell differentiation have not
been extensively explored.
Development of specialized effector T cell subsets such as
Th1, Th2, Th17, and Tfh cells from naïve precursors is believed
to be driven primarily by the presence or absence of specific
cytokines in the local environment at the time of priming. These
cytokines are primarily derived from innate immune cells upon
pathogen recognition, and in this way the innate immune system
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can instruct antigen-specific CD4+ T cells to differentiate into
effector cells with functions appropriate for eliminating differ-
ent types of pathogens. The relatively stable phenotypes of these
cells are believed to be the result of subset-specific expression of
“master” transcriptional regulators that control many of the phe-
notypic and functional characteristics of these cells (102). Because
distinct populations of Treg cells share expression of these key tran-
scription factors and often develop in parallel with their effector
cell counterparts, it is tempting to speculate that the same factors
induce the differentiation of phenotypically similar effector and
regulatory T cell (Treg) subsets. However, cases in which this has
been examined in detail have revealed important differences in the
differentiation of effector and Treg subsets.
The parallel development of Th1 cells and T-bet+ Treg cells
exemplifies the different ways in which effector and Tregs respond
to cytokine signals. Differentiation of IFN-γ-producing Th1 cells
is initiated by activation of the signaling adaptor and transcrip-
tion factor Stat1, which is phosphorylated following activation of
naïve conventional T cells through cytokines such as the type-1
IFNs, IFN-γ, or IL-27. Stat1 activates low-level expression of the
Th1-associated master transcription factor T-bet, which renders
cells sensitive to IL-12 by inducing expression of the IL-12 recep-
tor component IL-12Rβ2. IL-12-mediated activation of Stat4 then
drives the high-level T-bet expression required for full Th1 cell
differentiation. Similarly, Treg cells upregulated T-bet in response
to Stat1 activation following either IFN-γ or IL-27 stimulation
in vitro, and T-bet expression in Treg cells is dramatically reduced
in either Stat1- or IFN-γ-deficient mice (103, 104). However,
unlike IFN-γ stimulated effector T cells, Treg cells transiently
stimulated with Stat1 activating cytokines failed to efficiently
upregulate IL-12Rβ2 expression, and therefore could not complete
IL-12-dependent Th1 differentiation (103). The delayed induction
of IL-12Rβ2 was associated with the presence of inhibitory H3K27
tri-methyl histone methylation marks at the Il12rb2 promoter in
Treg cells. However, Treg cells did upregulate IL-12Rβ2 during
dysregulated inflammatory responses in vivo or prolonged acti-
vation in vitro and these cells were then rendered susceptible to
IL-12-mediated functional “reprograming,” losing their suppres-
sive function and upregulating expression of IFN-γ (103, 105).
Thus, differential sensitivity to IL-12 appears to be a major factor
underlying the relative ability of effector and Tregs to differentiate
into IFN-γ-producing cells. Additionally, during Mycobacterium
tuberculosis infection, pathogen-specific Treg cells are selectively
eliminated at later stages of infection in an IL-12-dependent man-
ner (94). Interestingly, unlike mice, in which it is difficult to detect
any IL-12-responsive or IFN-γ-producing Treg cells in the absence
of overt inflammatory pathology (95, 103, 104), Foxp3+IFN-γ+
Treg cells are readily identified in the peripheral blood of healthy
humans (27, 68). Although IFN-γ production by Treg cells can be
protective in the context of graft-versus-host disease (106), both
type-1 diabetes and multiple sclerosis have been associated with an
increase in IFN-γ–producing Treg cells, suggesting that redirected
Treg cells may contribute to autoimmune pathogenesis (66, 67).
Similar to these T-bet-expressing Treg cells that express CXCR3,
a large population of human and mouse Treg cells expresses the
Th17-associated chemokine receptor, CCR6 (107, 108), and in
human it is clear that many of these cells also express the key tran-
scriptional regulator of Th17 development RORγt (68, 69). CCR6
can direct Treg cell migration to sites of Th17-mediated inflam-
mation, indicating that these CCR6+ Treg cells may be particularly
potent suppressors of Th17 responses (109). CCR6+RORγt+ cells
were generated in vitro from Treg cells stimulated in the presence
of Th17 polarizing cytokines such as IL-1, IL-23, IL-6, and TGF-β,
but this was also associated with downregulation of Foxp3 and
loss of suppressor function (110), and this differs from the highly
suppressive CCR6+ Treg cells found in vivo. Interestingly, Treg
cell expression of the signaling adaptor and transcription factor
Stat3 was found to be essential for their ability to properly regulate
Th17 cell responses in vivo, and loss of Stat3 resulted in decreased
CCR6 expression by Treg cells and impaired their migration to
the intestines (64). Surprisingly, rather than the pro-inflammatory
Stat3 activating cytokine IL-6 that drives Th17 cell differentiation,
it was the anti-inflammatory cytokine IL-10 that promoted the
Stat3 phosphorylation in Treg cells required for suppression of
Th17-mediated autoimmune disease (111). Thus, as with Th1-
associated Treg cells, the development of Th17-associated CCR6+
Treg cells appears to be molecularly distinct from canonical Th17
cell differentiation.
Aside from the aforementioned studies on the development
of the Th1- and Th17-associated Treg cells, the differentiation of
other specialized Treg cell populations has not been extensively
studied. These include Bcl-6+ T “follicular regulatory” (Tfr) cells
that express the B cell-associated chemokine receptor CXCR5,
localize to B cell follicles and germinal centers in the secondary
lymphoid tissues and regulate the magnitude and output of the
germinal center response (112, 113). These Tfr cells develop in par-
allel to Bcl-6+ T follicular helper (Tfh) cells that promote humoral
immunity, and share some of their developmental requirements
such as CD28 mediated co-stimulation and signaling lymphocytic
activation molecule-associated protein (SAP)-dependent interac-
tion with B cells. However, a recent study found that the tran-
scription factor NFAT2 was required for CXCR5 expression in
Tfr, but not Tfh (114), further supporting the notion that effec-
tor and Tregs use distinct molecular pathways to achieve similar
phenotypes.
In addition to signals regulating their functional differentiation,
responding T cells also receive anatomical directions so that they
are targeted to the appropriate non-lymphoid tissue sites. This has
been best explored in the skin and intestines, where it seems that
signals from distinct tissue DCs program the migratory behavior
of the responding T cells in either the skin- or intestine-draining
lymphoid tissues (98, 115). This is, at least in part, due to the pres-
ence of specific vitamin metabolites in these different tissue sites.
Whereas CD103+ DCs in the intestine convert dietary vitamin A
to RA that induces expression of the intestinal homing receptors
α4β7 integrin and CCR9 on responding T cells (116), skin DCs can
convert sunlight-derived vitamin D into the active 1,25(OH)2D3
form, which induces T cell expression of CCR10, the receptor for
the epithelial chemokine CCL27 that is produced in abundance
by skin keratinocytes (117). Although many of these tissue signals
are likely sensed by both effector and Tregs (118), Treg cells dis-
play some unique tissue-migratory characteristics. For example,
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Treg cells selectively express the orphan G-protein-coupled recep-
tor, GPR15, and loss of this receptor resulted in impaired Treg
cell migration to the large intestinal lamina propria and dysreg-
ulated intestinal immune responses (119). GPR15 expression in
Treg cells was dependent on TGF-β1 signaling and on the presence
of intestinal commensal bacteria, indicating that Treg cells can
adopt unique tissue-specific phenotypes based on sensing local
environmental stimuli.
SUPPRESSIVE MECHANISMS OF Treg CELLS
Although Treg cells clearly have an important role in maintaining
immune tolerance and preventing autoimmune disease develop-
ment, the functional mechanisms by which Treg cell accomplish
these tasks in vivo are still not well understood. A key concept
that has emerged, however, is that Treg cells are functionally
heterogeneous, and that the importance of any given mecha-
nism of immune suppression is tissue- and context-dependent.
Indeed, to date, deletion of any single mechanism of Treg cell-
mediated immune suppression has not recapitulated the pheno-
types observed in Treg cell-deficient mice, indicating that Treg
cells use multiple inhibitory mechanisms that are at least partially
redundant.
The immunosuppressive mechanisms ascribed to Treg cells
thus far can broadly be divided into those that inhibit the acti-
vation and function of antigen-presenting cells, the production
of inhibitory cytokines that act directly on T cells, disruption of
effector T cell responses through deprivation of key cytokines or
metabolites, and even direct cytolysis of target cells. Although these
mechanisms have been reviewed extensively elsewhere (120, 121),
we will briefly touch on some of these as they relate to tissue- and
inflammation-specific Treg cell functions.
That Treg cells function differently in different tissue sites is
best exemplified by the fact that Treg cells in lymphoid and non-
lymphoid organs seem to use distinct regulatory mechanisms that
can differentially inhibit T cell priming or effector function. For
example, deletion of IL-10 specifically in Treg cells results in devel-
opment of spontaneous colitis, as well as exaggerated immune
responses in skin and lung (122). In contrast, Treg-specific deletion
of CTLA-4 results in systemic autoimmunity associated with dys-
regulated activation of T cells in secondary lymphoid tissues and
lymhoproliferation (123). Indeed, one key mechanism by which
Treg cells blunt T cell responses is by regulating DC abundance
(124, 125), and by maintaining DCs in a less stimulatory state by
CTLA-4-mediated stripping of the co-stimulatory ligands, CD80
and CD86 (123, 126). Analysis of Treg cell behavior in secondary
lymphoid tissues showed that they serially interact with DCs, and
that this in turn inhibited stable contacts between DCs and naïve
CD4+ T cells, preventing their activation and priming (127, 128).
It is therefore intriguing to speculate that Treg production of IL-10
is a major mechanism by which these cells regulate inflammation
at environmental interfaces, whereas CTLA-4-dependent regula-
tion of DC function is a regulatory mechanism that predominates
in secondary lymphoid tissues where it controls the initial acti-
vation and expansion of naïve autoreactive T cells. Accordingly,
although CTLA-4 is expressed by most Treg cells, production of
IL-10 is limited to effector Treg cells that upregulate expression
of the transcription factor Blimp-1 upon activation (70). That
IL-10 production is dramatically enriched in human Treg cells
that phenotypically resemble Th1 and Th17 cells further suggests
that IL-10 is particularly important for regulation of these types
of inflammatory responses (68).
In addition to inhibition of DC function and production of
immunoregulatory cytokines such as IL-10,TGF-β, and IL-35,Treg
cells can function by limiting the availability of key metabolites
and cytokines to effector T cells. This can occur indirectly, as Treg
cells promote expression of indolamine 2,3-dioxygenase (IDO) by
DCs. IDO is a potent regulatory molecule, which catabolizes tryp-
tophan, reducing the availability of this important amino acid and
in the process producing kynurenine, an endogenous ligand for
the aryl hydrocarbon receptor that can dampen effector T cell dif-
ferentiation (129, 130). Additionally, production of adenosine by
Treg cells due to their expression of the ectoenzymes CD39/CD73
contributes to their suppressive function in vitro and in vivo (131).
Finally,due to their constitutive expression of the high-affinity IL-2
receptor,Treg cells have been thought to function in part by seques-
tering IL-2 from responding CD4+ and CD8+ T cells. However, by
controlling the concentration of available IL-2, Treg cells can actu-
ally promote the generation of certain types of pro-inflammatory
effector cells. For instance, IL-2 signaling via Stat5 potently inhibits
Th17 cell development (132), and therefore by limiting IL-2 avail-
ability Treg cells can actually promote Th17 cell differentiation and
immune responses to infection with the fungal pathogen Candida
albicans (133, 134). Similarly, IL-2 signaling limits Tfh differen-
tiation, and Treg cells are required for efficient Tfh development
and germinal center responses during influenza infection (135).
Thus, rather than being strictly immunosuppressive, by influenc-
ing the immune environment Treg cells can contribute to efficient
pathogen clearance and memory formation.
A hallmark of the adaptive immune system is its ability
in healthy individuals to mount robust responses to invading
pathogens and dangerous toxins without causing excessive tissue
damage or development of autoimmunity. Despite the insights
into the various immunosuppressive mechanisms employed by
Treg cells, a key unresolved question is how Treg cells suppress
responses in such an antigen-specific way and are capable of dis-
criminating between beneficial and harmful immune responses.
Several lines of evidence indicate that a sizable population of
functionally competent T cells capable of causing autoimmunity
is actively suppressed by Treg cells. For instance, transfer of Treg
cell-depleted naïve T cells into lymphopenic mice rapidly causes
colitis and wasting disease (136). Additionally, depletion of Treg
cells in adult mice results in the rapid activation of CD4+ effector T
cells and development of severe autoinflammatory disease within
~10 days (124). Together, these data demonstrate that potentially
harmful cells are present in the normal T cell repertoire, and that
Treg cells do not permanently inactivate all autoreactive cells. Sup-
pression of these cells must be maintained in the face of various
infections, tissue damage, and sterile inflammatory responses that
require the immune system’s attention, raising the question of how
these cells are kept in check during induction of strong immune
responses to foreign antigens.
As discussed above, suppressing DC activity is an effective
strategy for preventing the priming of autoreactive T cells in
steady-state conditions. However, Treg cell-mediated suppression
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of DCs is quickly overcome during infection as a result of direct
pathogen recognition via various pathogen sensing systems such as
TLRs (39, 137), through activation by pro-inflammatory cytokines
(138), or by “licensing” of DCs via CD40 stimulation from acti-
vated T cells (139). Additionally, pro-inflammatory cytokines
made during infection such as IL-1, IL-6, IL-12, and type-1 IFNs
can subvert Treg cell function either directly (94, 140), or by
rendering effector T cells “resistant” to Treg cell-mediated sup-
pression (58, 141), and this is required to generate appropri-
ate anti-pathogen responses. Combined with the extensive tissue
damage and release of autoantigens that can accompany infection,
this would appear to provide ample opportunity for function-
ally competent autoreactive T cells to escape Treg cell-mediated
suppression and undergo activation/functional differentiation in
parallel with pathogen-specific cells. However, despite the fact that
infection is believed to trigger autoimmune disease in certain sus-
ceptible individuals and animal models, in most cases infections
are resolved without development of corresponding autoimmune
sequela. This concept is well-illustrated by the demyelinating dis-
ease that develops following infection with a neurotropic strain
of murine hepatitis virus (MHV). Depletion of Treg cells in this
context has little or no effect on the magnitude of the anti-viral
immune response or viral clearance, but greatly exacerbates neu-
rological pathology and the activation of myelin-specific T cells
(142), indicating that at least in this case Treg cells are selec-
tively modulating the activation and functional differentiation of
self-reactive T cells.
The mechanisms by which Treg cells restrict the activation of
self-reactive cells while allowing anti-pathogen responses to occur
remain poorly understood. The fact that these cells would be
expected to encounter either self- or foreign antigen presented
by the same populations of APCs and in the same cytokine envi-
ronment indicates that suppression in this case must be exquisitely
antigen-specific. However, most functional mechanisms ascribed
to Treg cells (inhibition of DC function, production of immuno-
suppressive cytokines, IL-2 deprivation, metabolic disruption of
effector T cells, etc.) would be expected to operate non-specifically
on most T cells in the local area. One possibility that must be
considered is that due to their self-reactivity, Treg cells directly
compete with other autoreactive cells for access to the limited
amount of any given self-antigen presented by DCs in secondary
lymphoid tissues (Figure 1). In such a competition, Treg cells
may have a distinct advantage due to their selection in the thy-
mus based on high-affinity interaction with self-antigen, and their
increased expression of adhesion and co-stimulatory receptors
such as LFA-1 that promote stable T cell:DC interactions (11).
Consistent with this notion, Treg cells could outcompete naïve T
cells of the same specificity for access to DCs when co-cultured
in vitro (143). Although the limited understanding of Treg cell
specificity has precluded a comprehensive test of this possibility
in vivo, it is interesting to note that only Treg cells from male
mice can effectively ameliorate autoimmune prostatitis caused
by Treg cell depletion due to neonatal thymectomy (144). Con-
versely, autoimmune oophoritis is most effectively controlled by
Treg cells from female mice, particularly those isolated from the
tissue-draining lymph nodes (145). Thus, despite the fact that
both male and female Treg cells presumably contain specificities
FIGURE 1 | A model for antigen-specific function ofTregs during
infection is shown. During pathogen encounter, activated antigen-
presenting cells present both self- and pathogen-derived antigens to CD4+
T cells. Whereas pathogen-specific effector T cells are activated (left),
competition for access to antigen with Treg cells prevents the activation of
autoreactive effector T cells and maintains self-tolerance (right).
for shared and ubiquitously expressed self-antigens present in the
prostate and ovaries, these were not sufficient to prevent disease
development, indicating a tremendous degree of antigen speci-
ficity in these regulatory responses. Additionally, Treg cells with
a limited TCR repertoire were unable to ameliorate experimen-
tal graft-versus-host-disease as well as those with a more diverse
repertoire, and this may reflect a decreased ability to compete with
effector cells for access to alloantigen. Finally, anti-CD3 therapy
for autoimmunity may work in part by allowing small popula-
tions of Treg cells that are“constrained”to specific TCR-dependent
niches to expand non-specifically, potentially allowing them to
better compete for autoantigen with effector T cells (146).
TISSUE-SUPPORT FUNCTIONS OF Treg CELLS
Activated tissue-resident Treg have been found in multiple tissues
such as skin, gut, lung, liver, solid tumors, muscle, and visceral adi-
pose tissue (VAT). As discussed, these tissue Treg cells have altered
phenotypes, distinct TCR repertoires, and function differently
than Treg cells from lymphoid organs (44, 55, 147, 148). Addition-
ally, some of these Treg cell populations may fulfill tissue-specific
functions that are not directly related to their immune functions,
and this was recently reviewed by some of the driving researchers in
this field (149). For example,VAT Treg cells are a well-characterized
population, which were found to specifically express peroxisome
proliferator-activated receptor (PPAR)-γ. PPAR-γ, which is con-
sidered to be a master regulator of adipocyte differentiation, was
recently reported to be a crucial molecule in VAT Treg cell accumu-
lation, phenotype, and function. Mice lacking PPAR-γ specifically
in Treg cells showed reduced Treg cell numbers specifically in VAT
and PPAR-γ expression by VAT Treg cells was necessary for com-
plete restoration of insulin sensitivity in obese mice (148). Sim-
ilarly, muscle Treg cells express the growth factor amphiregulin,
which acts directly on muscle satellite cells in vitro and improves
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muscle repair in vivo (147). However, in the existing models of
tissue homeostasis, it has been difficult to test whether expression
of a tissue-specific factor such as PPAR-γ or amphiregulin consti-
tutes a specialized state of the Treg to meet the specific needs of
the tissue, or whether it is required for the maintenance of Treg in
the tissue. A reduction in Treg numbers in the tissue would likely
result in prolonged inflammation, which itself could impair the
elaboration of normal tissue-repair mechanisms. The concept of
specific tissue-support roles of Treg cells that operate independent
of their anti-inflammatory functions can definitively be tested by
deletion of the respective genes in Treg cells, or by uncoupling Treg
removal from inflammation. One way to achieve the latter would
be to perform tissue-repair assays in RAG-deficient mice in which
Treg deficiency would not cause inflammation due to the absence
of effector T cells. This approach would conclusively answer how
much of the observed tissue-support functions of Treg cells are
due to their ability to control inflammatory responses that impair
normal tissue homeostasis.
REGULATORY MEMORY
The concept of regulatory memory has emerged in recent years,
as multiple studies have demonstrated that the regulatory arm
of the immune system can provide immunoprotection to tran-
siently encountered antigens (55, 150). Following expression of
a neo-tissue-antigen, antigen-specific Tregs become activated and
recruited to the target tissue. After preventing or resolving the
primary inflammation, these activated Treg reside in the tissue
even in the absence of antigen and upon re-encounter of the
same antigen they suppress a secondary inflammatory response.
Importantly, they do this more efficiently than during the primary
encounter displaying similarity to typical tissue-resident effector
memory T cells. These Treg cells that reside in the tissues have
been termed memory Treg (mTreg) cells. mTreg cells have been
described in murine skin where they control autoimmunity in
response to inducible antigen expression (55), and in following
allogeneic pregnancy (150). Indeed, successful pregnancy requires
the activity of maternal Treg cells specific for fetal allo-antigens.
These fetal-specific maternal Treg cells develop as pTreg cells dur-
ing pregnancy and persist at elevated levels after delivery. These
persistent Treg cells maintain tolerance to pre-encountered fetal
antigen and rapidly re-accumulate during subsequent pregnancy
rendering the secondary pregnancy more resilient to inflammatory
insults. However, it is important to point out that although in the
transgenic system (in which antigen expression could be turned on
and off pharmacologically) it is clear that mTreg cell maintenance
was antigen-independent (55), in the case of allo-specific fetal tol-
erance one cannot exclude the possibility that persistent antigen
[e.g., microchimerism (151)] is responsible for the maintenance
of Treg rather than true antigen-independent memory. Clarifica-
tion of this point will be crucial before fetal-specific mTreg can be
exploited therapeutically.
The discovery of memory Treg raises some obvious ques-
tions: what are the evolutionary target-antigens of mTreg cells? In
other words, which antigens are expressed/present intermittently
and thus require regulatory memory to last between exposures?
Although most self-antigens are likely persistently expressed, some,
such as proteins in female breast milk, pregnancy-related antigens,
and fetal antigens are encountered intermittently. In these cases,
the initial expression of the neo-self-antigen or fetal antigens
could recruit antigen-specific Treg cells to the respective tissue
(i.e., breast, uterus) to then dampen any inflammation upon re-
encounter of the antigen in the tissue. This mechanism would
increase the success of subsequent pregnancies. Thus, one could
speculate that mTreg-specific for intermittently expressed anti-
gens are a mechanism devised to face the challenges and changes
that accompany sexual reproduction in mammals. In this way,
mTreg are similar to pTreg, which seem to have evolved to miti-
gate the maternal–fetal conflict (152). Subsequently, both regula-
tory cell types may evolutionarily have been adapted to mediate
microbiota-specific tolerance (33). Microbial antigens present at
body surfaces may also be antigens we are only exposed to intermit-
tently depending on changes in the respective flora and on breaches
of the epithelial surface of skin or gut that result in increased release
of microbial antigens. Thus, mTreg cells may be a useful mecha-
nism to avoid inflammation in response to spikes in exposure to
normal microbial flora at body surfaces. Other examples of inter-
mittent antigen-exposure that may require regulatory memory
are food antigens and allergens that the gut and skin are exposed
to. The existence of allergen-specific mTreg in healthy individuals
has not been formally shown but the success of allergen-specific
immunotherapy relies on the induction of specific Treg cells that
persist over long periods of time (153).
Which tissues/situations are amenable to the induction and
maintenance of mTreg? Organs with environmental surfaces such
as the skin, gut, and lungs have the highest likelihood of a barrier
breach, and therefore, one might hypothesize that these organs
have a battalion of self-reactive (and/or microbiota-specific?)
mTreg cells positioned to prevent excessive inflammation and tis-
sue damage in case of barrier breach. Indeed, this may have driven
the ability of certain epithelial tissues to support mTreg cell main-
tenance (discussed further below). Additionally, it is possible that
the regenerative capacity of a tissue is crucial for the development
of mTreg cells. mTreg cells only make sense in tissues that can
recover after inflammatory damage. Relatively, non-regenerative
tissues such as the pancreas are perhaps less likely to harbor mTreg
cells since the pancreatic islets are destroyed in the inflammatory
response in type-1 diabetes and regulatory memory would not
serve subsequent organ protection. In this context, it is possible
that tissue stem cells instruct regulatory memory formation to
allow faster regeneration in future inflammatory settings. Indeed,
the immunomodulatory potential of stem cells, and in particular
mesenchymal stem cells (MSCs), has been studied extensively in
recent years. MSCs are pluripotent cells that are present in mul-
tiple tissues, including bone marrow, adipose tissue, skin, muscle,
blood, and placenta (154). MSCs were shown to induce Treg cells
in vitro via their production of prostaglandin E(2) and TGF-β
(155). Additionally, they modulate their environment by secretion
of mediators such as IDO and IL-10. Due to their immunomodula-
tory functions, numerous clinical studies using MSCs are currently
underway to treat inflammatory diseases such as graft-versus-
host disease and autoimmunity (156). Stem cells have potentially
evolved their ability to induce Treg cells because they seem to
require them for their maintenance. For instance, Treg cells are
attracted to the bone marrow by the stem cell chemoattractant
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CXCL12 (SDF-1) (157). This localization to the niche was cru-
cial for the preservation of the hematopoietic stem-cell niche in
the bone marrow as Treg cell depletion resulted in a loss of allo-
hematopoietic stem cells (158). Thus, Treg cells (and specifically
mTreg cells) are potentially involved in preserving stem-cell niches
from immune attacks and this may be one way in which they
provide critical tissue-support functions.
CONTROL OF Treg CELL MAINTENANCE
Due to their potent immunosuppressive function, manipulation
of Treg cell abundance is an attractive therapeutic strategy to either
boost or inhibit immune responses in a variety of clinical settings
(159). However, competition for growth and survival factors acts
to limit the size of the Treg cell pool in vivo, and as a result clinical
trials of adoptive Treg cell therapy have failed to achieve long-term
cell engraftment or substantial clinical benefit (79). Although work
over the last 10 years has defined several factors that help regulate
Treg cell homeostasis, an integrated model of how Treg cell abun-
dance, function, and distribution is controlled during normal and
pathological immune responses is still lacking. A better under-
standing of the mechanisms regulating the abundance of different
Treg cell populations is crucial for developing therapies to boost
their activity to treat autoimmunity and prevent graft rejection, or
to inhibit Treg cells in the contexts of cancer and chronic infection.
In conventional CD8+ and CD4+Foxp3+ effector T cells, it
has become clear that different populations of naïve, effector, and
memory T cells have distinct homeostatic requirements, and that
this helps preserve the functional diversity of effector and mem-
ory T cells while ensuring that an adequate pool of naïve T cells
is maintained in order to respond to new threats (160). This is
in large part due to changes in the requirements that these cells
have for different cytokines that signal through receptors utilizing
the γc receptor subunit such as IL-2, IL-7, and IL-15. That Treg
cells occupied their own homeostatic niches was apparent from
early experiments in which Treg cells underwent robust popula-
tion expansion and ameliorated autoimmune disease development
when transferred into Foxp3 mutant mice lacking endogenous
Treg cells (9). A similar niche-filling capacity of Treg cells is
observed when Treg cells are acutely depleted (161). That Treg
cells could be sub-divided into populations with different home-
ostatic behaviors (and therefore likely subject to distinct sets of
proliferative and survival signals) has been appreciated for some
time (82). However, the precise nature of these homeostatic niches
remains poorly understood.
Consistent with their constitutive expression of the high-
affinity IL-2 receptor component CD25, it has become clear that
IL-2 plays a central role in Treg cell function and homeostasis.
Accordingly, defects in IL-2 or various components of the IL-2
receptor lead to development of autoimmune/inflammatory dis-
eases associated with Treg cell dysfunction. Treg cells themselves
do not produce IL-2, and instead are stimulated in a paracrine
fashion by IL-2 produced by activated conventional T cells (162).
Through regulation of anti-apoptotic proteins such as Bcl-2 and
Mcl-1, IL-2 can deliver potent survival signals to Treg cells (161,
163). Additionally, IL-2 can potently drive Treg cell proliferation,
especially when present in excess during niche-filling or when
administered as super-agonistic IL-2/α-IL-2 immune complexes
(161, 164). Paradoxically, after the identification of Foxp3 as a
molecular marker of Treg cells it became apparent that the numer-
ical deficiency in peripheral Treg cells in peripheral tissues in the
absence of IL-2 signaling is relatively mild (165, 166), and correct-
ing these deficiencies by knocking out the pro-apoptotic factor
Bim failed to restore full Treg cell function in IL-2-deficient mice
(167). Taken together, these data indicate that maintenance of at
least some Treg cell populations is IL-2-independent, and that the
effects of IL-2 on Treg cell function in vivo are more qualitative
rather than quantitative. Indeed, a recent analysis of IL-2 signal-
ing in Treg cells demonstrated that rather than acting as a trophic
factor for all Treg cells, IL-2 signaling in vivo is largely restricted to
“central” Treg cells that access sites of paracrine IL-2 production in
the secondary lymphoid tissues via expression of the chemokine
receptor CCR7 (25). This quiescent population of Treg cells was
particularly sensitive to genetic or antibody-mediated blockade of
IL-2 signaling, whereas rapidly proliferating “effector” Treg cells
were effectively maintained in the absence of IL-2. IL-2 also pro-
motes specific effector functions in Treg cells such as expression of
CTLA-4 (167). As CTLA-4 expression by Treg cells in secondary
lymphoid organs help prevent the initial activation and differenti-
ation of autoreactive cells, selective loss of these central Treg cells
helps explain why autoimmunity develops in the absence of IL-2
or CD25 despite the presence of effector Treg cells with at least
some functional capacity.
In contrast to the IL-2-dependent central Treg cells, the abun-
dance of CCR7− effector Treg cells is most profoundly influenced
by signals through the TCR and associated co-stimulatory recep-
tors such as CD28 and ICOS. That effector Treg cells compete for
access to these signals is indicated by the fact that abundance of
these cells is intimately linked to the number of antigen-presenting
DCs (125). Moreover, the fact that DC-mediated Treg cell popu-
lation expansion occurred even when IL-2 signaling was blocked
indicates that signals through either the TCR or IL-2 act in sepa-
rate pathways to control Treg cell abundance (25, 168). Consistent
with this, although IL-2 signaling was not associated with Treg
cell proliferation in central Treg cells, the high rate of homeostatic
proliferation of effector Treg cells was completely dependent on
continued TCR signaling (168). Moreover, effector Treg cells have
a CD25loBcl-2loMcl-1lo phenotype indicative of IL-2 deprivation,
and accordingly are highly apoptotic. Thus, after losing access to
IL-2-dependent survival signals in secondary lymphoid tissues,
effector Treg cells in non-lymphoid organs appear to balance rapid
TCR-dependent cell proliferation with a high-rate of apoptotic cell
death to maintain their steady-state abundance. In tissues such as
the intestines, this creates a largely self-renewing Treg cell pool
specific for local antigens that are effectively maintained despite
low levels of cellular immigration (25).
Among the co-stimulatory receptors, loss of CD28 has the most
dramatic impact of Treg cell abundance (169). However, this may
be largely due to defective Treg cell development in the thymus
as deleting CD28 specifically in Treg cells after their development
did not recapitulate this phenotype, although the CD28-deficient
Treg cells were functionally impaired (170). However, blockade of
ICOS signaling causes a rapid decline in the abundance of effec-
tor Treg cells in vivo (25), and this can accelerate development of
organ-specific autoimmune disease (171). Interestingly, this was
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not associated with defects in effector Treg cell proliferation, indi-
cating that ICOS signaling may regulate effector Treg cell survival,
perhaps through engagement of the PI3K/Akt signaling pathway.
The dependence of effector Treg cells on TCR and co-
stimulatory signals, and their competition for access to DCs raises
the possibility that effector Treg cells exist in multiple TCR-
dependent “micro-niches” as was recently described for conven-
tional CD4+ T cells (92). In this scenario, Treg cells specific for any
given autoantigen must compete with one another for access to
antigen-bearing DCs, thereby linking the abundance of any given
Treg cell specificity to the amount of autoantigen presented, and
ensuring that a diverse TCR repertoire is maintained in effector
Treg cells. Indeed, this is consistent with the data demonstrat-
ing that particular TCR specificities are enriched in specific tissue
sites (33, 53).
Unlike effector Treg cells that appear to depend on continued
TCR and co-stimulatory signals for their maintenance, mem-
ory Treg cells can reside in non-lymphoid tissues such as the
skin for extended periods in the absence of continued antigen-
receptor signaling, raising the question of how these populations
are maintained (44, 59). Additionally, memory Treg cells displayed
a high-rate of homeostatic proliferation even after antigen with-
drawal (59). The continued proliferation and thus maintenance
of memory Treg cells may be a consequence of their not requiring
many of the signals thought to be essential for the responses of
effector T cells, such as Akt and mTOR and becoming relatively
independent of TCR-signals after initial activation (172). Addi-
tionally, in the absence of the continued TCR and co-stimulatory
receptor signals that maintain effector Treg cells, it is likely that
memory Treg cells rely instead on specific cytokine signals for
their homeostatic maintenance. Surprisingly, although IL-2 was
required for the development of memory Treg cells from naïve
precursors in the secondary lymphoid tissues, memory Treg cells
in the skin showed decreased CD25 expression and maintenance of
these cutaneous cells was IL-2-independent. However, IL-7 recep-
tor expression was dramatically upregulated on these cells, and
blockade of IL-7R signaling resulted in the loss of memory Treg
cells in the skin but not the skin-draining lymph node (49).
That maintenance of mTreg cells in the skin is IL-7-dependent
raises the important question of how expression of IL-7R is regu-
lated in these cells in such a tissue-specific manner. Expression of
IL-7R in conventional T cells is controlled in large part by the tran-
scription factor, Foxo1, which in T cells is inactivated and removed
from the nucleus after phosphorylation by activated Akt following
TCR stimulation (173). However, despite the fact that Treg cells
rely on continued Foxo1 activity for their suppressive function,
most Treg cells in secondary lymphoid organs express low levels
of IL-7R (49, 174). This prevents Treg cells from competing with
conventional naïve and memory T cells for access to IL-7 produced
by stromal cells in these tissues, and implies that IL-7R expression
is differentially regulated in conventional T cells and Treg cells.
By contrast, antigen-specific Treg cells in murine skin uniformly
expressed high levels of IL-7R both in the presence or absence
of antigen expression (Iris K. Gratz, unpublished observations).
Although the tissue-specific signals directing IL-7R expression by
Treg cells in the skin have not been identified, this results in the
maintenance of a stable population of tissue-resident mTreg cells
even in the absence of continued antigen or IL-2. However, the
importance of IL-7 in the maintenance of memory Treg cells in
tissues other than the skin has not been examined. For instance,
due to their expression of CD122 and the γc chain, Treg cells are
equipped to respond to IL-15 trans-presented on the surface of IL-
15/IL-15Rα expressing cells, and rather than IL-7, this may help
maintain mTreg cells in tissues rich in IL-15 such as the intestine.
Collectively, these recent data support the concept that rather
than occupying a single homeostatic niche, multiple pathways
of homeostatic maintenance exist for distinct populations of
Treg cells in different tissue sites. These include IL-2-dependent
maintenance of central Treg cells in secondary lymphoid organs,
TCR/ICOS-dependent maintenance of effector Treg cells in
inflamed non-lymphoid tissues, and IL-7-dependent maintenance
of memory Treg cells in the skin (Figure 2).
CLINICAL IMPLICATIONS
Therapies to prevent allograft rejection or treat autoimmune
diseases have long relied on general immunosuppression using
broadly acting and non-specific medications. Treg cells represent
a promising new avenue with the possibility of long-lived and
antigen-specific tolerance to self- or foreign-antigens. Reported
clinical trials have focused on the expansion of Treg cells in vivo and
ex vivo (175). Applications of both polyclonally expanded Treg-
populations and antigen-specific Treg cells are currently moving
into the clinic, and results have thus far shown acceptable safety
and promising efficacy of the treatment (176). Conversely, inhibi-
tion of Treg cell function may enhance immunotherapy to cancer,
and help promote resolution of chronic infection.
Resolution of the particular issues of Treg cell biology raised
in the above will certainly help in the targeted development of
Treg cell-based therapies. For instance, defining Treg cell speci-
ficity would allow for a more precise targeting of Treg cell-based
therapies to the most appropriate antigens. Many antigens that
are targeted by effector cells in autoimmune inflammatory dis-
eases have been defined [e.g., BP180 in bullous pemphigoid (177),
desmoglein 3 in pemphigus vulgaris (178), and insulin and other
antigens in type-1 diabetes (179)]. Additionally, there is consider-
able hope that allo-antigen-specific Treg cells will show superior
suppressive function compared to polyclonal Treg cells in prevent-
ing transplant rejection and graft-versus-host disease. By iden-
tifying appropriate antigens, antigen-specific Treg cells could be
expanded ex vivo and adoptively transferred. Upon interaction
with tissue DCs in vivo, these Treg cells would likely acquire a
tissue-tropic chemokine receptor phenotype and migrate to the
same target tissues as their effector T cell counterparts. However,
clinical trials with antigen-specific ex vivo expanded Treg cells are
just starting (180) and it will be crucial to analyze migratory pat-
terns, maintenance in tissues, and suppressive function of these
Treg cells.
In addition to controlling their specificity, the identification of
tissue- and inflammation-specific Treg cells subsets implies that
targeting the “correct” Treg cell population will be critical for
effective Treg cell-based immunotherapy. One can envision expos-
ing Treg cells in vitro to defined cytokine- and co-stimulatory
conditions to induce the expression of specific homing recep-
tors and functional modules with the goal to guide them to the
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FIGURE 2 | Multiple mechanisms ofTreg cell maintenance. Different
populations of Treg cells are subject to distinct homeostatic constraints.
Central Treg cells (cTr) access paracrine IL-2 in secondary lymphoid tissues
(left), whereas maintenance of effector Treg cells (eTr) in non-lymphoid tissues
depends on continued TCR/ICOS signals (middle), and memory Treg cells
(mTr) in the skin are supported by IL-7/IL-7R-mediated survival signals (right).
appropriate target tissue and hone their suppressive mechanisms.
These applications of ex vivo expanded Treg cells will benefit
tremendously from a better understanding of the development of
tissue- and inflammation-specific Treg cell populations, and the
control of the immunosuppressive mechanisms they employ. The
end results of these efforts to better target Treg cells would include
not only increased therapeutic efficacy but also a simultaneous
decrease in unwanted off-target effects that could be envisioned
upon Treg cell transfer (e.g., generalized immunosuppression or
increased risk of tumor development).
A major advantage of adoptive Treg cell therapy is its poten-
tial for long-lasting effects without the need to persistently treat
with immunosuppressive drugs. However, current applications
have struggled with instability and loss of Treg cells after transfer.
Therefore, identifying the factors that govern Treg maintenance
will not only allow for better survival of transferred Treg cells but
will also open the door to new therapies aimed at manipulating
(both positively and negatively) the abundance of endogenous
Treg cells in different tissue sites for treating autoimmunity, pro-
moting transplantation tolerance, enhancing cancer immunother-
apy, or resolving chronic infection. Additionally, the identification
of key functional mechanisms and molecules that support Treg
cell maintenance and function in specific tissue sites will have
a tremendous impact on development of immunotherapies. In
this regard, a recent study indicating that the surface molecule
neuropilin-1 is essential for Treg cell maintenance and function
in tumor environments, but not in other tissue sites, is particu-
larly promising for efforts to inhibit Treg cells as an adjunct cancer
immunotherapy (181).
The various developmental stages of Treg cells have only just
begun to be defined and understood. For most clinically relevant
inflammatory settings, it is not known which stage, naïve, central,
effector, or memory (or subtypes of these), is most suitable for
therapeutic interventions. However, due to their presumed sta-
bility and antigen-independent maintenance, memory Treg cells
seem ideally suited to mediate long-term immunoregulatory ben-
efits. However, memory Treg cells have only been described in
the skin and the uterus and it is an open question whether they
can be found in other target organs and whether their require-
ments for maintenance differ in different tissue sites. Addition-
ally, better defining the developmental relationship between these
different Treg cell populations could provide new insights into
how to best promote the generation of immunoprotective Treg
cells.
The manipulation of Treg cells to alter the outcome of inflam-
matory responses is the most obvious translational application
of our increasing knowledge of Treg cell biology. However, the
recent studies indicating that Treg cells can have specialized tissue-
support functions that may lead to a broader range of Treg cell
applications. Defining tissue-support functions could yield bet-
ter therapies for wound healing/tissue-regeneration, metabolic
regulation, and potentially other tissue-specific functions. How-
ever, more studies on how tissue-resident Treg cells differ from
each other and their counterparts found in secondary lymphoid
organs are required before we can attempt to therapeutically use
and manipulate these populations. Importantly, basic research in
this and other key areas of Treg cell biology highlighted in this
review will continue in an iterative process with clinical trials,
each informing the other as the therapeutic potential of Treg cells
is fully realized.
ACKNOWLEDGMENTS
The authors thank J. Michael Stolley for his help with the figures.
The authors’ work has been supported by grants from the NIH

























































Gratz and Campbell Organ-specific Treg cells
to Iris K. Gratz (AR064554) and Daniel J. Campbell (AR055695,
AI067750, AI085130, and HL098067). Iris K. Gratz is also sup-
ported by a grant from the Austrian Science Fund (FWF) (J2997-
B13) and by the Dystrophic Epidermolysis Bullosa Research
Association (DEBRA) International and DEBRA Austria.
REFERENCES
1. Curotto de Lafaille MA, Lafaille JJ. Natural and adaptive Foxp3+ regulatory T
cells: more of the same or a division of labor? Immunity (2009) 30:626–35.
doi:10.1016/j.immuni.2009.05.002
2. Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L,
et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked
syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet (2001) 27:20–1.
doi:10.1038/83713
3. Rai E, Wakeland EK. Genetic predisposition to autoimmunity – what have we
learned? Semin Immunol (2011) 23:67–83. doi:10.1016/j.smim.2011.01.015
4. Veiga-Parga T, Sehrawat S, Rouse BT. Role of regulatory T cells during virus
infection. Immunol Rev (2013) 255:182–96. doi:10.1111/imr.12085
5. Waldmann H, Hilbrands R, Howie D, Cobbold S. Harnessing FOXP3+ regu-
latory T cells for transplantation tolerance. J Clin Invest (2014) 124:1439–45.
doi:10.1172/JCI67226
6. Nishikawa H, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Curr
Opin Immunol (2014) 27C:1–7. doi:10.1016/j.coi.2013.12.005
7. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-
tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains
(CD25). Breakdown of a single mechanism of self-tolerance causes various
autoimmune diseases. J Immunol (1995) 155:1151–64.
8. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the
transcription factor Foxp3. Science (2003) 299:1057–61. doi:10.1126/science.
1079490
9. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and
function of CD4+CD25+ regulatory T cells. Nat Immunol (2003) 4:330–6.
doi:10.1038/ni904
10. Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG, Rudensky AY.
Regulatory T cell lineage specification by the forkhead transcription factor
foxp3. Immunity (2005) 22:329–41. doi:10.1016/j.immuni.2005.01.016
11. Huehn J, Siegmund K, Lehmann JCU, Siewert C, Haubold U, Feuerer M,
et al. Developmental stage, phenotype, and migration distinguish naive- and
effector/memory-like CD4+ regulatory T cells. J Exp Med (2004) 199:303–13.
doi:10.1084/jem.20031562
12. Sather BD, Treuting P, Perdue N, Miazgowicz M, Fontenot JD, Rudensky
AY, et al. Altering the distribution of Foxp3(+) regulatory T cells results
in tissue-specific inflammatory disease. J Exp Med (2007) 204:1335–47.
doi:10.1084/jem.20070081
13. Suffia I, Reckling SK, Salay G, Belkaid Y. A role for CD103 in the retention
of CD4+CD25+ Treg and control of Leishmania major infection. J Immunol
(2005) 174:5444–55. doi:10.4049/jimmunol.174.9.5444
14. Chen Z, Herman AE, Matos M, Mathis D, Benoist C. Where CD4+CD25+ T
reg cells impinge on autoimmune diabetes. J Exp Med (2005) 202:1387–97.
doi:10.1084/jem.20051409
15. Nguyen LT, Jacobs J, Mathis D, Benoist C. Where FoxP3-dependent regulatory
T cells impinge on the development of inflammatory arthritis. Arthritis Rheum
(2007) 56:509–20. doi:10.1002/art.22272
16. Szanya V, Ermann J, Taylor C, Holness C, Fathman CG. The subpopula-
tion of CD4+CD25+ splenocytes that delays adoptive transfer of diabetes
expresses L-selectin and high levels of CCR7. J Immunol (2002) 169:2461–5.
doi:10.4049/jimmunol.169.5.2461
17. Dudda JC, Perdue N, Bachtanian E, Campbell DJ. Foxp3+ regulatory T cells
maintain immune homeostasis in the skin. J Exp Med (2008) 205:1559–65.
doi:10.1084/jem.20072594
18. Denning TL, Kim G, Kronenberg M. Cutting edge: CD4+CD25+ regulatory
T cells impaired for intestinal homing can prevent colitis. J Immunol (2005)
174:7487–91. doi:10.4049/jimmunol.174.12.7487
19. Willerford DM, Chen J, Ferry JA, Davidson L, Ma A, Alt FW. Interleukin-
2 receptor alpha chain regulates the size and content of the peripheral
lymphoid compartment. Immunity (1995) 3:521–30. doi:10.1016/1074-
7613(95)90180-9
20. Sadlack B, Merz H, Schorle H, Schimpl A, Feller AC, Horak I. Ulcerative colitis-
like disease in mice with a disrupted interleukin-2 gene. Cell (1993) 75:253–61.
doi:10.1016/0092-8674(93)80067-O
21. Singh B, Read S, Asseman C, Malmström V, Mottet C, Stephens LA, et al.
Control of intestinal inflammation by regulatory T cells. Immunol Rev (2001)
182:190–200. doi:10.1034/j.1600-065X.2001.1820115.x
22. Hirahara K, Liu L, Clark RA, Yamanaka K, Fuhlbrigge RC, Kupper TS. The
majority of human peripheral blood CD4+CD25highFoxp3+ regulatory T
cells bear functional skin-homing receptors. J Immunol (2006) 177:4488–94.
doi:10.4049/jimmunol.177.7.4488
23. Iellem A, Colantonio L, D’Ambrosio D. Skin-versus gut-skewed homing
receptor expression and intrinsic CCR4 expression on human peripheral
blood CD4+CD25+ suppressor T cells. Eur J Immunol (2003) 33:1488–96.
doi:10.1002/eji.200323658
24. Klonowski KD, Williams KJ, Marzo AL, Blair DA, Lingenheld EG, Lefrançois
L. Dynamics of blood-borne CD8 memory T cell migration in vivo. Immunity
(2004) 20:551–62. doi:10.1016/S1074-7613(04)00103-7
25. Smigiel KS, Richards E, Srivastava S, Thomas KR, Dudda JC, Klonowski
KD, et al. CCR7 provides localized access to IL-2 and defines homeosta-
tically distinct regulatory T cell subsets. J Exp Med (2014) 211:121–36.
doi:10.1084/jem.20131142
26. Grindebacke H, Stenstad H, Quiding-Järbrink M, Waldenström J, Adlerberth
I, Wold AE, et al. Dynamic development of homing receptor expression and
memory cell differentiation of infant CD4+CD25high regulatory T cells.
J Immunol (2009) 183:4360–70. doi:10.4049/jimmunol.0901091
27. Thornton AM, Korty PE, Tran DQ, Wohlfert EA, Murray PE, Belkaid Y, et al.
Expression of Helios, an Ikaros transcription factor family member, differen-
tiates thymic-derived from peripherally induced Foxp3+ T regulatory cells.
J Immunol (2010) 184:3433–41. doi:10.4049/jimmunol.0904028
28. Weiss JM, Bilate AM, Gobert M, Ding Y, Curotto de Lafaille MA, Parkhurst
CN, et al. Neuropilin 1 is expressed on thymus-derived natural regulatory T
cells, but not mucosa-generated induced Foxp3+ T reg cells. J Exp Med (2012)
209(1723–1742):S1. doi:10.1084/jem.20120914
29. Yadav M, Louvet C, Davini D, Gardner JM, Martinez-Llordella M, Bailey-
Bucktrout S, et al. Neuropilin-1 distinguishes natural and inducible regulatory
T cells among regulatory T cell subsets in vivo. J Exp Med (2012) 209:1713–22.
doi:10.1084/jem.20120822
30. Coombes JL, Siddiqui KRR, Arancibia-Cárcamo CV, Hall J, Sun C-M, Belkaid
Y, et al. A functionally specialized population of mucosal CD103+ DCs induces
Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mecha-
nism. J Exp Med (2007) 204:1757–64. doi:10.1084/jem.20070590
31. Sun C-M, Hall JA, Blank RB, Bouladoux N, Oukka M, Mora JR, et al.
Small intestine lamina propria dendritic cells promote de novo generation
of Foxp3 T reg cells via retinoic acid. J Exp Med (2007) 204:1775–85.
doi:10.1084/jem.20070602
32. Jaensson E, Uronen-Hansson H, Pabst O, Eksteen B, Tian J, Coombes JL, et al.
Small intestinal CD103+ dendritic cells display unique functional properties
that are conserved between mice and humans. J Exp Med (2008) 205:2139–49.
doi:10.1084/jem.20080414
33. Lathrop SK, Bloom SM, Rao SM, Nutsch K, Lio C-W, Santacruz N, et al. Periph-
eral education of the immune system by colonic commensal microbiota. Nature
(2011) 478:250–4. doi:10.1038/nature10434
34. Hand TW, Dos Santos LM, Bouladoux N, Molloy MJ, Pagán AJ, Pepper M,
et al. Acute gastrointestinal infection induces long-lived microbiota-
specific T cell responses. Science (2012) 337:1553–6. doi:10.1126/science.
1220961
35. Takeuchi H, Yokota A, Ohoka Y, Kagechika H, Kato C, Song S-Y, et al. Effi-
cient induction of CCR9 on T cells requires coactivation of retinoic acid
receptors and retinoid X receptors (RXRs): exaggerated T Cell homing to the
intestine by RXR activation with organotins. J Immunol (2010) 185:5289–99.
doi:10.4049/jimmunol.1000101
36. Sutmuller RPM, den Brok MHMGM, Kramer M, Bennink EJ, Toonen LWJ,
Kullberg B-J, et al. Toll-like receptor 2 controls expansion and function of reg-
ulatory T cells. J Clin Invest (2006) 116:485–94. doi:10.1172/JCI25439
37. Hall JA, Bouladoux N, Sun CM, Wohlfert EA, Blank RB, Zhu Q, et al. Com-
mensal DNA limits regulatory T cell conversion and is a natural adjuvant
of intestinal immune responses. Immunity (2008) 29:637–49. doi:10.1016/j.
immuni.2008.08.009

























































Gratz and Campbell Organ-specific Treg cells
38. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, et al. Reciprocal
developmental pathways for the generation of pathogenic effector TH17 and
regulatory T cells. Nature (2006) 441:235–8. doi:10.1038/nature04753
39. Pasare C, Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+
T cell-mediated suppression by dendritic cells. Science (2003) 299:1033–6.
doi:10.1126/science.1078231
40. Arpaia N, Campbell C, Fan X, Dikiy S, van der Veeken J, deRoos P, et al. Metabo-
lites produced by commensal bacteria promote peripheral regulatory T-cell
generation. Nature (2013) 504:451–5. doi:10.1038/nature12726
41. Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly-Y M,
et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg
cell homeostasis. Science (2013) 341:569–73. doi:10.1126/science.1241165
42. Furusawa Y, Obata Y, Fukuda S, Endo TA, Nakato G, Takahashi D, et al. Com-
mensal microbe-derived butyrate induces the differentiation of colonic regu-
latory T cells. Nature (2013) 504:446–50. doi:10.1038/nature12721
43. Maslowski KM, Vieira AT, Ng A, Kranich J, Sierro F, Yu D, et al. Regulation
of inflammatory responses by gut microbiota and chemoattractant receptor
GPR43. Nature (2009) 461:1282–6. doi:10.1038/nature08530
44. Sanchez Rodriguez R, Pauli ML, Neuhaus IM, Yu SS, Arron ST, Harris HW,
et al. Memory regulatory T cells reside in human skin. J Clin Invest (2014)
124:1027–36. doi:10.1172/JCI72932
45. Siegmund K, Feuerer M, Siewert C, Ghani S, Haubold U, Dankof A,
et al. Migration matters: regulatory T-cell compartmentalization determines
suppressive activity in vivo. Blood (2005) 106:3097–104. doi:10.1182/blood-
2005-05-1864
46. Freyschmidt E-J, Mathias CB, Diaz N, MacArthur DH, Laouar A, Manjunath
N, et al. Skin inflammation arising from cutaneous regulatory T cell deficiency
leads to impaired viral immune responses. J Immunol (2010) 185:1295–302.
doi:10.4049/jimmunol.0903144
47. Halabi-Tawil M, Ruemmele FM, Fraitag S, Rieux-Laucat F, Neven B, Brousse N,
et al. Cutaneous manifestations of immune dysregulation, polyendocrinopa-
thy, enteropathy, X-linked (IPEX) syndrome. Br J Dermatol (2009) 160:645–51.
doi:10.1111/j.1365-2133.2008.08835.x
48. Godfrey VL, Wilkinson JE, Russell LB. X-linked lymphoreticular disease in the
scurfy (sf) mutant mouse. Am J Pathol (1991) 138:1379–87.
49. Gratz IK, Truong H-A, Yang SH-Y, Maurano MM, Lee K, Abbas AK, et al.
Cutting edge: memory regulatory T cells require IL-7 and not IL-2 for
their maintenance in peripheral tissues. J Immunol (2013) 190(9):4483–7.
doi:10.4049/jimmunol.1300212
50. Matsue H, Bergstresser PR, Takashima A. Keratinocyte-derived IL-7 serves as
a growth factor for dendritic epidermal T cells in mice. J Immunol (1993)
151:6012–9.
51. Soontrapa K,Honda T,Sakata D,Yao C,Hirata T,Hori S,et al. Prostaglandin E2-
prostaglandin E receptor subtype 4 (EP4) signaling mediates UV irradiation-
induced systemic immunosuppression. Proc Natl Acad Sci U S A (2011)
108:6668–73. doi:10.1073/pnas.1018625108
52. Guilliams M, Crozat K, Henri S, Tamoutounour S, Grenot P, Devilard E, et al.
Skin-draining lymph nodes contain dermis-derived CD103- dendritic cells
that constitutively produce retinoic acid and induce Foxp3+ regulatory T cells.
Blood (2010) 115:1958–68. doi:10.1182/blood-2009-09-245274
53. Lathrop SK, Santacruz NA, Pham D, Luo J, Hsieh C-S. Antigen-specific periph-
eral shaping of the natural regulatory T cell population. J Exp Med (2008)
205:3105–17. doi:10.1084/jem.20081359
54. Killebrew JR, Perdue N, Kwan A, Thornton AM, Shevach EM, Campbell DJ.
A self-reactive TCR drives the development of Foxp3+ regulatory T cells
that prevent autoimmune disease. J Immunol (2011) 187:861–9. doi:10.4049/
jimmunol.1004009
55. Rosenblum MD, Gratz IK, Paw JS, Lee K, Marshak-Rothstein A, Abbas AK.
Response to self antigen imprints regulatory memory in tissues. Nature (2011)
480:538–42. doi:10.1038/nature10664
56. Grice EA, Segre JA. The skin microbiome. Nat Rev Microbiol (2011) 9:244–53.
doi:10.1038/nrmicro2537
57. Naik S, Bouladoux N, Wilhelm C, Molloy MJ, Salcedo R, Kastenmuller W, et al.
Compartmentalized control of skin immunity by resident commensals. Science
(2012) 337:1115–9. doi:10.1126/science.1225152
58. Schenten D, Nish SA, Yu S, Yan X, Lee HK, Brodsky I, et al. Signaling through
the adaptor molecule MyD88 in CD4+ T cells is required to overcome suppres-
sion by regulatory T cells. Immunity (2014) 40:78–90. doi:10.1016/j.immuni.
2013.10.023
59. Gratz IK, Rosenblum MD, Maurano MM, Paw JS, Truong H-A, Marshak-
Rothstein A, et al. Cutting edge: self-antigen controls the balance between effec-
tor and regulatory T cells in peripheral tissues. J Immunol (2014) 192:1351–5.
doi:10.4049/jimmunol.1301777
60. Mikhak Z, Fleming CM, Medoff BD, Thomas SY, Tager AM, Campanella GS,
et al. STAT1 in peripheral tissue differentially regulates homing of antigen-
specific Th1 and Th2 cells. J Immunol (2006) 176:4959–67. doi:10.4049/
jimmunol.176.8.4959
61. Hirota K, Yoshitomi H, Hashimoto M, Maeda S, Teradaira S, Sugimoto N,
et al. Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints
via CCL20 in rheumatoid arthritis and its animal model. J Exp Med (2007)
204:2803–12. doi:10.1084/jem.20071397
62. Lord GM, Rao RM, Choe H, Sullivan BM, Lichtman AH, Luscinskas FW, et al.
T-bet is required for optimal proinflammatory CD4+ T-cell trafficking. Blood
(2005) 106:3432–9. doi:10.1182/blood-2005-04-1393
63. Koch MA, Tucker-Heard G, Perdue NR, Killebrew JR, Urdahl KB, Camp-
bell DJ. The transcription factor T-bet controls regulatory T cell homeostasis
and function during type 1 inflammation. Nat Immunol (2009) 10:595–602.
doi:10.1038/ni.1731
64. Chaudhry A, Rudra D, Treuting P, Samstein RM, Liang Y, Kas A, et al. CD4+
regulatory T cells control TH17 responses in a Stat3-dependent manner. Science
(2009) 326:986–91. doi:10.1126/science.1172702
65. Zheng Y, Chaudhry A, Kas A, deRoos P, Kim JM, Chu T-T, et al. Regulatory
T-cell suppressor program co-opts transcription factor IRF4 to control T(H)2
responses. Nature (2009) 458:351–6. doi:10.1038/nature07674
66. Dominguez-Villar M, Baecher-Allan CM, Hafler DA. Identification of T helper
type 1-like, Foxp3+ regulatory T cells in human autoimmune disease. Nat Med
(2011) 17:673–5. doi:10.1038/nm.2389
67. McClymont SA, Putnam AL, Lee MR, Esensten JH, Liu W, Hulme MA, et al.
Plasticity of human regulatory T cells in healthy subjects and patients with type
1 diabetes. J Immunol (2011) 186:3918–26. doi:10.4049/jimmunol.1003099
68. Duhen T, Duhen R, Lanzavecchia A, Sallusto F, Campbell DJ. Functionally dis-
tinct subsets of human FOXP3+ Treg cells that phenotypically mirror effector
Th cells. Blood (2012) 119:4430–40. doi:10.1182/blood-2011-11-392324
69. Ayyoub M, Deknuydt F, Raimbaud I, Dousset C, Leveque L, Bioley G, et al.
Human memory FOXP3+ Tregs secrete IL-17 ex vivo and constitutively express
the TH17 lineage-specific transcription factor RORγt. Proc Natl Acad Sci U S
A (2009) 106:8635–40. doi:10.1073/pnas.0900621106
70. Cretney E, Xin A, Shi W, Minnich M, Masson F, Miasari M, et al. The transcrip-
tion factors Blimp-1 and IRF4 jointly control the differentiation and function of
effector regulatory T cells. Nat Immunol (2011) 12:304–11. doi:10.1038/ni.2006
71. Makita S, Kanai T, Oshima S, Uraushihara K, Totsuka T, Sawada T, et al.
CD4+CD25bright T cells in human intestinal lamina propria as regulatory
cells. J Immunol (2004) 173:3119–30. doi:10.4049/jimmunol.173.5.3119
72. Feger U, Luther C, Poeschel S, Melms A, Tolosa E, Wiendl H. Increased fre-
quency of CD4+ CD25+ regulatory T cells in the cerebrospinal fluid but not in
the blood of multiple sclerosis patients. Clin Exp Immunol (2007) 147:412–8.
doi:10.1111/j.1365-2249.2006.03271.x
73. Cao D, Malmström V, Baecher-Allan C, Hafler D, Klareskog L, Trollmo C. Iso-
lation and functional characterization of regulatory CD25brightCD4+ T cells
from the target organ of patients with rheumatoid arthritis. Eur J Immunol
(2003) 33:215–23. doi:10.1002/immu.200390024
74. Korn T, Reddy J, Gao W, Bettelli E, Awasthi A, Petersen TR, et al. Myelin-
specific regulatory T cells accumulate in the CNS but fail to control autoim-
mune inflammation. Nat Med (2007) 13:423–31. doi:10.1038/nm1564
75. Tang Q, Adams JY, Penaranda C, Melli K, Piaggio E, Sgouroudis E, et al. Central
role of defective interleukin-2 production in the triggering of islet autoimmune
destruction. Immunity (2008) 28:687–97. doi:10.1016/j.immuni.2008.03.016
76. Long SA, Buckner JH. CD4+FOXP3+ T regulatory cells in human autoimmu-
nity: more than a numbers game. J Immunol (2011) 187:2061–6. doi:10.4049/
jimmunol.1003224
77. Ohkura N, Hamaguchi M, Morikawa H, Sugimura K, Tanaka A, Ito Y, et al. T
cell receptor stimulation-induced epigenetic changes and Foxp3 expression are
independent and complementary events required for Treg cell development.
Immunity (2012) 37:785–99. doi:10.1016/j.immuni.2012.09.010
78. Arvey A, van der Veeken J, Samstein RM, Feng Y, Stamatoyannopoulos
JA, Rudensky AY. Inflammation-induced repression of chromatin bound by
the transcription factor Foxp3 in regulatory T cells. Nat Immunol (2014)
15(6):580–7. doi:10.1038/ni.2868

























































Gratz and Campbell Organ-specific Treg cells
79. Hippen KL, Riley JL, June CH, Blazar BR. Clinical perspectives for regula-
tory T cells in transplantation tolerance. Semin Immunol (2011) 23:462–8.
doi:10.1016/j.smim.2011.07.008
80. Herold KC, Vignali DAA, Cooke A, Bluestone JA. Type 1 diabetes: translating
mechanistic observations into effective clinical outcomes. Nat Rev Immunol
(2013) 13:243–56. doi:10.1038/nri3422
81. Bensinger SJ, Bandeira A, Jordan MS, Caton AJ, Laufer TM. Major histocom-
patibility complex class II-positive cortical epithelium mediates the selection
of CD4(+)25(+) immunoregulatory T cells. J Exp Med (2001) 194:427–38.
doi:10.1084/jem.194.4.427
82. Fisson S, Darrasse-Jèze G, Litvinova E, Septier F, Klatzmann D, Liblau R, et al.
Continuous activation of autoreactive CD4+ CD25+ regulatory T cells in the
steady state. J Exp Med (2003) 198:737–46. doi:10.1084/jem.20030686
83. Hsieh C-S, Liang Y, Tyznik AJ, Self SG, Liggitt D, Rudensky AY. Recognition of
the peripheral self by naturally arising CD25+ CD4+ T cell receptors. Immunity
(2004) 21:267–77. doi:10.1016/j.immuni.2004.07.009
84. Walker LSK, Chodos A, Eggena M, Dooms H, Abbas AK. Antigen-dependent
proliferation of CD4+ CD25+ regulatory T cells in vivo. J Exp Med (2003)
198:249–58. doi:10.1084/jem.20030315
85. Jordan MS, Boesteanu A, Reed AJ, Petrone AL, Holenbeck AE, Lerman MA,
et al. Thymic selection of CD4+CD25+ regulatory T cells induced by an ago-
nist self-peptide. Nat Immunol (2001) 2:301–6. doi:10.1038/86302
86. Klein L, Khazaie K, von Boehmer H. In vivo dynamics of antigen-specific reg-
ulatory T cells not predicted from behavior in vitro. Proc Natl Acad Sci U S A
(2003) 100:8886–91. doi:10.1073/pnas.1533365100
87. Aschenbrenner K, D’Cruz LM, Vollmann EH, Hinterberger M, Emmerich J,
Swee LK, et al. Selection of Foxp3+ regulatory T cells specific for self anti-
gen expressed and presented by Aire+ medullary thymic epithelial cells. Nat
Immunol (2007) 8:351–8. doi:10.1038/ni1444
88. Malchow S, Leventhal DS, Nishi S, Fischer BI, Shen L, Paner GP, et al. Aire-
dependent thymic development of tumor-associated regulatory T cells. Science
(2013) 339:1219–24. doi:10.1126/science.1233913
89. Daniely D, Kern J, Cebula A, Ignatowicz L. Diversity of TCRs on natural
Foxp3+ T cells in mice lacking Aire expression. J Immunol (2010) 184:6865–73.
doi:10.4049/jimmunol.0903609
90. Dongre AR, Kovats S, deRoos P, McCormack AL, Nakagawa T, Paharkova-
Vatchkova V, et al. In vivo MHC class II presentation of cytosolic proteins
revealed by rapid automated tandem mass spectrometry and functional analy-
ses. Eur J Immunol (2001) 31:1485–94. doi:10.1002/1521-4141(200105)31:
5<1485::AID-IMMU1485>3.0.CO;2-A
91. Bautista JL, Lio C-WJ, Lathrop SK, Forbush K, Liang Y, Luo J, et al. Intraclonal
competition limits the fate determination of regulatory T cells in the thymus.
Nat Immunol (2009) 10:610–7. doi:10.1038/ni.1739
92. Singh NJ, Bando JK, Schwartz RH. Subsets of nonclonal neighboring CD4+ T
cells specifically regulate the frequency of individual antigen-reactive T cells.
Immunity (2012) 37:735–46. doi:10.1016/j.immuni.2012.08.008
93. Belkaid Y, Tarbell K. Regulatory T cells in the control of host-microorganism
interactions (*). Annu Rev Immunol (2009) 27:551–89. doi:10.1146/annurev.
immunol.021908.132723
94. Shafiani S, Dinh C, Ertelt JM, Moguche AO, Siddiqui I, Smigiel KS, et al.
Pathogen-specific Treg cells expand early during mycobacterium tuberculo-
sis infection but are later eliminated in response to Interleukin-12. Immunity
(2013) 38:1261–70. doi:10.1016/j.immuni.2013.06.003
95. Zhao J, Zhao J, Fett C, Trandem K, Fleming E, Perlman S. IFN-γ- and
IL-10-expressing virus epitope-specific Foxp3(+) T reg cells in the central
nervous system during encephalomyelitis. J Exp Med (2011) 208:1571–7.
doi:10.1084/jem.20110236
96. Suffia IJ, Reckling SK, Piccirillo CA, Goldszmid RS, Belkaid Y. Infected site-
restricted Foxp3+ natural regulatory T cells are specific for microbial antigens.
J Exp Med (2006) 203:777–88. doi:10.1084/jem.20052056
97. Pacholczyk R, Kern J, Singh N, Iwashima M, Kraj P, Ignatowicz L. Nonself-
antigens are the cognate specificities of Foxp3+ regulatory T cells. Immunity
(2007) 27:493–504. doi:10.1016/j.immuni.2007.07.019
98. Campbell DJ, Butcher EC. Rapid acquisition of tissue-specific homing pheno-
types by CD4(+) T cells activated in cutaneous or mucosal lymphoid tissues.
J Exp Med (2002) 195:135–41. doi:10.1084/jem.20011502
99. Reinhardt RL, Bullard DC, Weaver CT, Jenkins MK. Preferential accumulation
of antigen-specific effector CD4 T cells at an antigen injection site involves
CD62E-dependent migration but not local proliferation. J Exp Med (2003)
197:751–62. doi:10.1084/jem.20021690
100. Fu H, Kishore M, Gittens B, Wang G, Coe D, Komarowska I, et al. Self-
recognition of the endothelium enables regulatory T-cell trafficking and
defines the kinetics of immune regulation. Nat Commun (2014) 5:3436.
doi:10.1038/ncomms4436
101. Chaudhry A, Rudensky AY. Control of inflammation by integration of envi-
ronmental cues by regulatory T cells. J Clin Invest (2013) 123:939–44.
doi:10.1172/JCI57175
102. Reiner SL. Development in motion: helper T cells at work. Cell (2007) 129:33–6.
doi:10.1016/j.cell.2007.03.019
103. Koch MA, Thomas KR, Perdue NR, Smigiel KS, Srivastava S, Campbell DJ.
T-bet(+) Treg cells undergo abortive Th1 cell differentiation due to impaired
expression of IL-12 receptor β2. Immunity (2012) 37:501–10. doi:10.1016/j.
immuni.2012.05.031
104. Hall AO, Beiting DP, Tato C, John B, Oldenhove G, Lombana CG, et al.
The cytokines interleukin 27 and interferon-γ promote distinct Treg cell
populations required to limit infection-induced pathology. Immunity (2012)
37:511–23. doi:10.1016/j.immuni.2012.06.014
105. Oldenhove G, Bouladoux N, Wohlfert EA, Hall JA, Chou D, Dos Santos L,
et al. Decrease of Foxp3+ Treg cell number and acquisition of effector cell
phenotype during lethal infection. Immunity (2009) 31:772–86. doi:10.1016/j.
immuni.2009.10.001
106. Koenecke C, Lee C-W, Thamm K, Föhse L, Schafferus M, Mittrücker H-W, et al.
IFN-γ production by allogeneic Foxp3+ regulatory T cells is essential for pre-
venting experimental graft-versus-host disease. J Immunol (2012) 189:2890–6.
doi:10.4049/jimmunol.1200413
107. Lim HW, Broxmeyer HE, Kim CH. Regulation of trafficking receptor expres-
sion in human forkhead box P3+ regulatory T cells. J Immunol (2006)
177:840–51. doi:10.4049/jimmunol.177.2.840
108. Kleinewietfeld M, Puentes F, Borsellino G, Battistini L, Rötzschke O, Falk
K. CCR6 expression defines regulatory effector/memory-like cells within the
CD25(+)CD4+ T-cell subset. Blood (2005) 105:2877–86. doi:10.1182/blood-
2004-07-2505
109. Yamazaki T, Yang XO, Chung Y, Fukunaga A, Nurieva R, Pappu B, et al. CCR6
regulates the migration of inflammatory and regulatory T cells. J Immunol
(2008) 181:8391–401. doi:10.4049/jimmunol.181.12.8391
110. Valmori D, Raffin C, Raimbaud I, Ayyoub M. Human RORγt+ TH17 cells
preferentially differentiate from naive FOXP3+Treg in the presence of lineage-
specific polarizing factors. Proc Natl Acad Sci U S A (2010) 107:19402–7.
doi:10.1073/pnas.1008247107
111. Chaudhry A, Samstein RM, Treuting P, Liang Y, Pils MC, Heinrich J-M,
et al. Interleukin-10 signaling in regulatory T cells is required for sup-
pression of Th17 cell-mediated inflammation. Immunity (2011) 34:566–78.
doi:10.1016/j.immuni.2011.03.018
112. Linterman MA, Pierson W, Lee SK, Kallies A, Kawamoto S, Rayner TF, et al.
Foxp3+ follicular regulatory T cells control the germinal center response. Nat
Med (2011) 17:975–82. doi:10.1038/nm.2425
113. Chung Y, Tanaka S, Chu F, Nurieva RI, Martinez GJ, Rawal S, et al. Follic-
ular regulatory T cells expressing Foxp3 and Bcl-6 suppress germinal center
reactions. Nat Med (2011) 17:983–8. doi:10.1038/nm.2426
114. Vaeth M, Müller G, Stauss D, Dietz L, Klein-Hessling S, Serfling E, et al.
Follicular regulatory T cells control humoral autoimmunity via NFAT2-
regulated CXCR5 expression. J Exp Med (2014) 211:545–61. doi:10.1084/jem.
20130604
115. Mora JR, Bono MR, Manjunath N, Weninger W, Cavanagh LL, Rosemblatt M,
et al. Selective imprinting of gut-homing T cells by Peyer’s patch dendritic cells.
Nature (2003) 424:88–93. doi:10.1038/nature01726
116. Iwata M, Hirakiyama A, Eshima Y, Kagechika H, Kato C, Song S-Y. Retinoic
acid imprints gut-homing specificity on T cells. Immunity (2004) 21:527–38.
doi:10.1016/j.immuni.2004.08.011
117. Sigmundsdottir H, Pan J, Debes GF, Alt C, Habtezion A, Soler D, et al.
DCs metabolize sunlight-induced vitamin D3 to “program” T cell attrac-
tion to the epidermal chemokine CCL27. Nat Immunol (2007) 8:285–93.
doi:10.1038/ni1433
118. Siewert C, Menning A, Dudda J, Siegmund K, Lauer U, Floess S, et al. Induc-
tion of organ-selective CD4+ regulatory T cell homing. Eur J Immunol (2007)
37:978–89. doi:10.1002/eji.200636575

























































Gratz and Campbell Organ-specific Treg cells
119. Kim SV, Xiang WV, Kwak C, Yang Y, Lin XW, Ota M, et al. GPR15-mediated
homing controls immune homeostasis in the large intestine mucosa. Science
(2013) 340:1456–9. doi:10.1126/science.1237013
120. Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev
Immunol (2008) 8:523–32. doi:10.1038/nri2343
121. Wing JB, Sakaguchi S. Multiple Treg suppressive modules and their adaptability.
Front Immunol (2012) 3:178. doi:10.3389/fimmu.2012.00178
122. Rubtsov YP, Rasmussen JP, Chi EY, Fontenot J, Castelli L, Ye X, et al. Regulatory
T cell-derived interleukin-10 limits inflammation at environmental interfaces.
Immunity (2008) 28:546–58. doi:10.1016/j.immuni.2008.02.017
123. Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z,
et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science (2008)
322:271–5. doi:10.1126/science.1160062
124. Kim JM, Rasmussen JP, Rudensky AY. Regulatory T cells prevent catastrophic
autoimmunity throughout the lifespan of mice. Nat Immunol (2007) 8:191–7.
doi:10.1038/ni1428
125. Darrasse-Jèze G, Deroubaix S, Mouquet H, Victora GD, Eisenreich T, Yao
K, et al. Feedback control of regulatory T cell homeostasis by dendritic cells
in vivo. J Exp Med (2009) 206:1853–62. doi:10.1084/jem.20090746
126. Qureshi OS, Zheng Y, Nakamura K, Attridge K, Manzotti C, Schmidt EM, et al.
Trans-endocytosis of CD80 and CD86: a molecular basis for the cell extrin-
sic function of CTLA-4. Science (2011) 332(6029):600–3. doi:10.1126/science.
1202947
127. Tang Q, Adams JY, Tooley AJ, Bi M, Fife BT, Serra P, et al. Visualizing regula-
tory T cell control of autoimmune responses in nonobese diabetic mice. Nat
Immunol (2006) 7:83–92. doi:10.1038/ni1289
128. Tadokoro CE, Shakhar G, Shen S, Ding Y, Lino AC, Maraver A, et al. Regulatory
T cells inhibit stable contacts between CD4+ T cells and dendritic cells in vivo.
J Exp Med (2006) 203:505–11. doi:10.1084/jem.20050783
129. Opitz CA, Litzenburger UM, Sahm F, Ott M, Tritschler I, Trump S, et al. An
endogenous tumour-promoting ligand of the human aryl hydrocarbon recep-
tor. Nature (2011) 478:197–203. doi:10.1038/nature10491
130. Mezrich JD, Fechner JH, Zhang X, Johnson BP, Burlingham WJ, Bradfield CA.
An interaction between kynurenine and the aryl hydrocarbon receptor can gen-
erate regulatory T cells. J Immunol (2010) 185:3190–8. doi:10.4049/jimmunol.
0903670
131. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, et al. Adeno-
sine generation catalyzed by CD39 and CD73 expressed on regulatory T cells
mediates immune suppression. J Exp Med (2007) 204:1257–65. doi:10.1084/
jem.20062512
132. Laurence A, Tato CM, Davidson TS, Kanno Y, Chen Z,Yao Z, et al. Interleukin-2
signaling via STAT5 constrains T helper 17 cell generation. Immunity (2007)
26:371–81. doi:10.1016/j.immuni.2007.02.009
133. Chen Y, Haines CJ, Gutcher I, Hochweller K, Blumenschein WM, McClana-
han T, et al. Foxp3(+) regulatory T cells promote T helper 17 cell develop-
ment in vivo through regulation of interleukin-2. Immunity (2011) 34:409–21.
doi:10.1016/j.immuni.2011.02.011
134. Pandiyan P, Conti HR, Zheng L, Peterson AC, Mathern DR, Hernández-Santos
N, et al. CD4(+)CD25(+)Foxp3(+) regulatory T cells promote Th17 cells
in vitro and enhance host resistance in mouse Candida albicans Th17 cell infec-
tion model. Immunity (2011) 34:422–34. doi:10.1016/j.immuni.2011.03.002
135. León B, Bradley JE, Lund FE, Randall TD, Ballesteros-Tato A. FoxP3+ reg-
ulatory T cells promote influenza-specific Tfh responses by controlling IL-2
availability. Nat Commun (2014) 5:3495. doi:10.1038/ncomms4495
136. Powrie F, Leach MW, Mauze S, Caddle LB, Coffman RL. Phenotypically
distinct subsets of CD4+ T cells induce or protect from chronic intesti-
nal inflammation in C. B-17 scid mice. Int Immunol (1993) 5:1461–71.
doi:10.1093/intimm/5.11.1461
137. Fehérvári Z, Sakaguchi S. Control of Foxp3+ CD25+CD4+ regulatory cell
activation and function by dendritic cells. Int Immunol (2004) 16:1769–80.
doi:10.1093/intimm/dxh178
138. Kubo T, Hatton RD, Oliver J, Liu X, Elson CO,Weaver CT. Regulatory T cell sup-
pression and anergy are differentially regulated by proinflammatory cytokines
produced by TLR-activated dendritic cells. J Immunol (2004) 173:7249–58.
doi:10.4049/jimmunol.173.12.7249
139. Ballesteros-Tato A, León B, Lund FE, Randall TD. CD4+ T helper cells use
CD154-CD40 interactions to counteract T reg cell-mediated suppression
of CD8+ T cell responses to influenza. J Exp Med (2013) 210:1591–601.
doi:10.1084/jem.20130097
140. Srivastava S, Koch MA, Pepper M, Campbell DJ. Type I interferons directly
inhibit regulatory T cells to allow optimal antiviral T cell responses during
acute LCMV infection. J Exp Med (2014). doi:10.1084/jem.20131556
141. Schneider A, Long SA, Cerosaletti K, Ni CT, Samuels P, Kita M, et al. Active
relapsing-remitting multiple sclerosis, effector T cell resistance to adaptive
Tregs involves IL-6-mediated signaling. Sci Transl Med (2013) 5:170ra15.
doi:10.1126/scitranslmed.3004970
142. Cervantes-Barragán L, Firner S, Bechmann I, Waisman A, Lahl K, Sparwasser T,
et al. Regulatory T cells selectively preserve immune privilege of self-antigens
during viral central nervous system infection. J Immunol (2012) 188:3678–85.
doi:10.4049/jimmunol.1102422
143. Onishi Y, Fehervari Z, Yamaguchi T, Sakaguchi S. Foxp3+ natural regula-
tory T cells preferentially form aggregates on dendritic cells in vitro and
actively inhibit their maturation. Proc Natl Acad Sci U S A (2008) 105:10113–8.
doi:10.1073/pnas.0711106105
144. Setiady YY, Ohno K, Samy ET, Bagavant H, Qiao H, Sharp C, et al. Phys-
iologic self antigens rapidly capacitate autoimmune disease-specific poly-
clonal CD4+CD25+ regulatory T cells. Blood (2006) 107:1056–62. doi:10.1182/
blood-2005-08-3088
145. Samy ET, Parker LA, Sharp CP, Tung KSK. Continuous control of autoim-
mune disease by antigen-dependent polyclonal CD4+CD25+ regulatory T cells
in the regional lymph node. J Exp Med (2005) 202:771–81. doi:10.1084/jem.
20041033
146. Nishio J, Feuerer M, Wong J, Mathis D, Benoist C. Anti-CD3 therapy
permits regulatory T cells to surmount T cell receptor-specified
peripheral niche constraints. J Exp Med (2010) 207:1879–89. doi:10.1084/jem.
20100205
147. Burzyn D, Kuswanto W, Kolodin D, Shadrach JL, Cerletti M, Jang Y, et al. A
special population of regulatory T cells potentiates muscle repair. Cell (2013)
155:1282–95. doi:10.1016/j.cell.2013.10.054
148. Cipolletta D, Feuerer M, Li A, Kamei N, Lee J, Shoelson SE, et al. PPAR-γ is a
major driver of the accumulation and phenotype of adipose tissue Treg cells.
Nature (2012) 486:549–53. doi:10.1038/nature11132
149. Burzyn D, Benoist C, Mathis D. Regulatory T cells in nonlymphoid tissues. Nat
Immunol (2013) 14:1007–13. doi:10.1038/ni.2683
150. Rowe JH, Ertelt JM, Xin L, Way SS. Pregnancy imprints regulatory memory
that sustains anergy to fetal antigen. Nature (2012) 490:102–6. doi:10.1038/
nature11462
151. Kinder JM, Jiang TT, Clark DR, Chaturvedi V, Xin L, Ertelt JM, et al. Pregnancy-
induced maternal regulatory T cells, bona fide memory or maintenance by
antigenic reminder from fetal cell microchimerism? Chimerism (2014) 5:16–9.
doi:10.4161/chim.28241
152. Samstein RM, Josefowicz SZ, Arvey A, Treuting PM, Rudensky AY. Extrathymic
generation of regulatory T cells in placental mammals mitigates maternal-fetal
conflict. Cell (2012) 150:29–38. doi:10.1016/j.cell.2012.05.031
153. Sabatos-Peyton CA, Verhagen J, Wraith DC. Antigen-specific immunotherapy
of autoimmune and allergic diseases. Curr Opin Immunol (2010) 22:609–15.
doi:10.1016/j.coi.2010.08.006
154. Plock JA, Schnider JT, Solari MG, Zheng XX, Gorantla VS. Perspectives on the
use of mesenchymal stem cells in vascularized composite allotransplantation.
Front Immunol (2013) 4:175. doi:10.3389/fimmu.2013.00175
155. English K, Ryan JM, Tobin L, Murphy MJ, Barry FP, Mahon BP. Cell contact,
prostaglandin E(2) and transforming growth factor beta 1 play non-redundant
roles in human mesenchymal stem cell induction of CD4+CD25(High) fork-
head box P3+ regulatory T cells. Clin Exp Immunol (2009) 156:149–60.
doi:10.1111/j.1365-2249.2009.03874.x
156. Stagg J, Galipeau J. Mechanisms of immune modulation by mesenchy-
mal stromal cells and clinical translation. Curr Mol Med (2013) 13:856–67.
doi:10.2174/1566524011313050016
157. Zou L, Barnett B, Safah H, Larussa VF, Evdemon-Hogan M, Mottram P, et al.
Bone marrow is a reservoir for CD4+CD25+ regulatory T cells that traffic
through CXCL12/CXCR4 signals. Cancer Res (2004) 64:8451–5. doi:10.1158/
0008-5472.CAN-04-1987
158. Fujisaki J, Wu J, Carlson AL, Silberstein L, Putheti P, Larocca R, et al. In vivo
imaging of Treg cells providing immune privilege to the haematopoietic stem-
cell niche. Nature (2011) 474:216–9. doi:10.1038/nature10160
159. Riley JL, June CH, Blazar BR. Human T regulatory cell therapy: take a
billion or so and call me in the morning. Immunity (2009) 30:656–65.
doi:10.1016/j.immuni.2009.04.006

























































Gratz and Campbell Organ-specific Treg cells
160. Boyman O, Krieg C, Homann D, Sprent J. Homeostatic maintenance of T
cells and natural killer cells. Cell Mol Life Sci (2012) 69:1597–608. doi:10.1007/
s00018-012-0968-7
161. Pierson W, Cauwe B, Policheni A, Schlenner SM, Franckaert D, Berges J, et al.
Antiapoptotic Mcl-1 is critical for the survival and niche-filling capacity of
Foxp3+ regulatory T cells. Nat Immunol (2013) 14:959–65. doi:10.1038/ni.2649
162. Setoguchi R, Hori S, Takahashi T, Sakaguchi S. Homeostatic maintenance of
natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2
and induction of autoimmune disease by IL-2 neutralization. J Exp Med (2005)
201:723–35. doi:10.1084/jem.20041982
163. Tai X, Erman B, Alag A, Mu J, Kimura M, Katz G, et al. Foxp3 transcrip-
tion factor is proapoptotic and lethal to developing regulatory T cells unless
counterbalanced by cytokine survival signals. Immunity (2013) 38:1116–28.
doi:10.1016/j.immuni.2013.02.022
164. Boyman O, Kovar M, Rubinstein MP, Surh CD, Sprent J. Selective stimulation
of T cell subsets with antibody-cytokine immune complexes. Science (2006)
311:1924–7. doi:10.1126/science.1122927
165. Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY. A function for interleukin
2 in Foxp3-expressing regulatory T cells. Nat Immunol (2005) 6:1142–51.
doi:10.1038/ni1263
166. Soper DM, Kasprowicz DJ, Ziegler SF. IL-2Rbeta links IL-2R signaling
with Foxp3 expression. Eur J Immunol (2007) 37:1817–26. doi:10.1002/eji.
200737101
167. Barron L, Dooms H, Hoyer KK, Kuswanto W, Hofmann J, O’Gorman WE, et al.
Cutting edge: mechanisms of IL-2-dependent maintenance of functional regu-
latory T cells. J Immunol (2010) 185:6426–30. doi:10.4049/jimmunol.0903940
168. Zou T, Satake A, Corbo-Rodgers E, Schmidt AM, Farrar MA, Maltzman JS, et al.
Cutting edge: IL-2 signals determine the degree of TCR signaling necessary to
support regulatory T cell proliferation in vivo. J Immunol (2012) 189:28–32.
doi:10.4049/jimmunol.1200507
169. Tang Q, Henriksen KJ, Boden EK, Tooley AJ, Ye J, Subudhi SK, et al. Cutting
edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells.
J Immunol (2003) 171:3348–52. doi:10.4049/jimmunol.171.7.3348
170. Zhang R, Huynh A, Whitcher G, Chang J, Maltzman JS, Turka LA. An oblig-
ate cell-intrinsic function for CD28 in Tregs. J Clin Invest (2013) 123:580–93.
doi:10.1172/JCI65013
171. Herman AE, Freeman GJ, Mathis D, Benoist C. CD4+CD25+ T regulatory
cells dependent on ICOS promote regulation of effector cells in the prediabetic
lesion. J Exp Med (2004) 199:1479–89. doi:10.1084/jem.20040179
172. Josefowicz SZ, Lu L-F, Rudensky AY. Regulatory T cells: mechanisms of dif-
ferentiation and function. Annu Rev Immunol (2012) 30:531–64. doi:10.1146/
annurev.immunol.25.022106.141623
173. Ouyang W, Li MO. Foxo: in command of T lymphocyte homeostasis and tol-
erance. Trends Immunol (2011) 32:26–33. doi:10.1016/j.it.2010.10.005
174. Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, et al. CD127 expression
inversely correlates with FoxP3 and suppressive function of human CD4+ T
reg cells. J Exp Med (2006) 203:1701–11. doi:10.1084/jem.20060772
175. Rosenblum MD, Gratz IK, Paw JS, Abbas AK. Treating human autoimmu-
nity: current practice and future prospects. Sci Transl Med (2012) 4:125sr1.
doi:10.1126/scitranslmed.3003504
176. Tang Q, Bluestone JA. Regulatory T-cell therapy in transplantation: mov-
ing to the clinic. Cold Spring Harb Perspect Med (2013):3(11):a015552.
doi:10.1101/cshperspect.a015552
177. Zillikens D. BP180 as the common autoantigen in blistering diseases with dif-
ferent clinical phenotypes. Keio J Med (2002) 51:21–8. doi:10.2302/kjm.51.21
178. Amagai M, Klaus-Kovtun V, Stanley JR. Autoantibodies against a novel epithe-
lial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell (1991)
67:869–77. doi:10.1016/0092-8674(91)90360-B
179. Roep BO, Peakman M. Antigen targets of type 1 diabetes autoimmunity. Cold
Spring Harb Perspect Med (2012) 2:a007781. doi:10.1101/cshperspect.a007781
180. Putnam AL, Safinia N, Medvec A, Laszkowska M, Wray M, Mintz MA,
et al. Clinical grade manufacturing of human alloantigen-reactive regula-
tory T cells for use in transplantation. Am J Transplant (2013) 13:3010–20.
doi:10.1111/ajt.12433
181. Delgoffe GM, Woo S-R, Turnis ME, Gravano DM, Guy C, Overacre AE, et al.
Stability and function of regulatory T cells is maintained by a neuropilin-1-
semaphorin-4a axis. Nature (2013) 501:252–6. doi:10.1038/nature12428
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 15 May 2014; accepted: 30 June 2014; published online: 15 July 2014.
Citation: Gratz IK and Campbell DJ (2014) Organ-specific and memory Treg cells:
specificity, development, function, and maintenance. Front. Immunol. 5:333. doi:
10.3389/fimmu.2014.00333
This article was submitted to Immunological Memory, a section of the journal Frontiers
in Immunology.
Copyright © 2014 Gratz and Campbell. This is an open-access article distributed under
the terms of the Creative Commons Attribution License (CC BY). The use, distribution
or reproduction in other forums is permitted, provided the original author(s) or licensor
are credited and that the original publication in this journal is cited, in accordance with
accepted academic practice. No use, distribution or reproduction is permitted which
does not comply with these terms.
www.frontiersin.org July 2014 | Volume 5 | Article 333 | 17
